{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T19:06:48Z","timestamp":1791745608342,"version":"4.3.4"},"reference-count":308,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"High-level Talents of Fujian University of Chinese Medicine","award":["X2019006-Talents"],"award-info":[{"award-number":["X2019006-Talents"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Apoptosis"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s10495-026-02347-6","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T13:18:25Z","timestamp":1778505505000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dynamic ecosystems of tumor drug resistance mechanisms: from molecular heterogeneity to systemic interventions"],"prefix":"10.1007","volume":"31","author":[{"given":"Qiaohong","family":"Bao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiali","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinmei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhizhe","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youfa","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"2347_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-89445-4","volume-title":"Drug resistance in cancer cells","author":"ZH Siddik","year":"2009","unstructured":"Siddik ZH, Mehta K (2009) Drug resistance in cancer cells. Springer US, New York, NY"},{"key":"2347_CR2","doi-asserted-by":"publisher","first-page":"5981","DOI":"10.1158\/1538-7445.am2025-5981","volume":"85","author":"Y Tang","year":"2025","unstructured":"Tang Y, Wang G, Lv T et al (2025) Abstract 5981: over 200! The largest BaF3-EGFR engineering cell lines collection, a useful platform for novel drug discovery. Cancer Res 85:5981\u20135981. https:\/\/doi.org\/10.1158\/1538-7445.am2025-5981","journal-title":"Cancer Res"},{"key":"2347_CR3","doi-asserted-by":"publisher","first-page":"a041331","DOI":"10.1101\/cshperspect.a041331","volume":"13","author":"E Dalla","year":"2023","unstructured":"Dalla E, Sreekumar A, Aguirre-Ghiso JA, Chodosh LA (2023) Dormancy in breast cancer. Cold Spring Harb Perspect Med 13:a041331. https:\/\/doi.org\/10.1101\/cshperspect.a041331","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2347_CR4","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41586-023-06342-8","volume":"620","author":"Y Goyal","year":"2023","unstructured":"Goyal Y, Busch GT, Pillai M et al (2023) Diverse clonal fates emerge upon drug treatment of homogeneous cancer cells. Nature 620:651\u2013659. https:\/\/doi.org\/10.1038\/s41586-023-06342-8","journal-title":"Nature"},{"key":"2347_CR5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/biom12010008","volume":"12","author":"A Nam","year":"2021","unstructured":"Nam A, Mohanty A, Bhattacharya S et al (2021) Dynamic phenotypic switching and group behavior help non-small cell lung cancer cells evade chemotherapy. Biomolecules 12:8. https:\/\/doi.org\/10.3390\/biom12010008","journal-title":"Biomolecules"},{"key":"2347_CR6","doi-asserted-by":"publisher","first-page":"109450","DOI":"10.1016\/j.isci.2024.109450","volume":"27","author":"J Zhou","year":"2024","unstructured":"Zhou J, Liu C, Tang Y et al (2024) Phenotypic switching as a non-genetic mechanism of resistance predicts antibody therapy regimens. Iscience 27:109450. https:\/\/doi.org\/10.1016\/j.isci.2024.109450","journal-title":"Iscience"},{"key":"2347_CR7","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/path.6034","volume":"259","author":"GA Pettitt","year":"2022","unstructured":"Pettitt GA, Hurst CD, Khan Z et al (2022) Development of resistance to FGFR inhibition in urothelial carcinoma via multiple pathways in vitro. J Pathol 259:220\u2013232. https:\/\/doi.org\/10.1002\/path.6034","journal-title":"J Pathol"},{"key":"2347_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-024-01623-z","author":"LK Godfrey","year":"2024","unstructured":"Godfrey LK, Forster J, Liffers S-T et al (2024) Pancreatic cancer acquires resistance to MAPK pathway inhibition by clonal expansion and adaptive DNA hypermethylation. Clin Epigenet. https:\/\/doi.org\/10.1186\/s13148-024-01623-z","journal-title":"Clin Epigenet"},{"key":"2347_CR9","doi-asserted-by":"publisher","first-page":"572","DOI":"10.20517\/cdr.2020.35","volume":"3","author":"AL Miller","year":"2020","unstructured":"Miller AL, Garcia PL, Gamblin TL et al (2020) Development of gemcitabine-resistant patient-derived xenograft models of pancreatic ductal adenocarcinoma. Cancer Drug Resist (alhambra Calif) 3:572\u2013585. https:\/\/doi.org\/10.20517\/cdr.2020.35","journal-title":"Cancer Drug Resist (alhambra Calif)"},{"key":"2347_CR10","doi-asserted-by":"publisher","first-page":"1023177","DOI":"10.3389\/fonc.2022.1023177","volume":"12","author":"B Huang","year":"2022","unstructured":"Huang B, Lang X, Li X (2022) The role of IL-6\/JAK2\/STAT3 signaling pathway in cancers. Front Oncol 12:1023177","journal-title":"Front Oncol"},{"key":"2347_CR11","doi-asserted-by":"publisher","first-page":"17443","DOI":"10.18632\/oncotarget.24734","volume":"9","author":"L Chen","year":"2018","unstructured":"Chen L, Wang S, Wang Y et al (2018) IL-6 influences the polarization of macrophages and the formation and growth of colorectal tumor. Oncotarget 9:17443\u201317454. https:\/\/doi.org\/10.18632\/oncotarget.24734","journal-title":"Oncotarget"},{"key":"2347_CR12","doi-asserted-by":"publisher","first-page":"6237","DOI":"10.3390\/ijms25116237","volume":"25","author":"SK Mandal","year":"2024","unstructured":"Mandal SK, Yadav P, Sheth RA (2024) The neuroimmune axis and its therapeutic potential for primary liver cancer. Int J Mol Sci 25:6237. https:\/\/doi.org\/10.3390\/ijms25116237","journal-title":"Int J Mol Sci"},{"key":"2347_CR13","doi-asserted-by":"publisher","first-page":"188623","DOI":"10.1016\/j.bbcan.2021.188623","volume":"1876","author":"M Luo","year":"2021","unstructured":"Luo M, Yang X, Chen H-N et al (2021) Drug resistance in colorectal cancer: An epigenetic overview. Biochimica et Biophysica Acta (BBA). Reviews Cancer 1876:188623. https:\/\/doi.org\/10.1016\/j.bbcan.2021.188623","journal-title":"Reviews Cancer"},{"key":"2347_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-021-00970-w","author":"X Li","year":"2021","unstructured":"Li X, Guo M, Hou B et al (2021) CRISPR\/Cas9 nanoeditor of double knockout large fragments of E6 and E7 oncogenes for reversing drugs resistance in cervical cancer. J Nanobiotechnol. https:\/\/doi.org\/10.1186\/s12951-021-00970-w","journal-title":"J Nanobiotechnol"},{"key":"2347_CR15","doi-asserted-by":"publisher","first-page":"9545","DOI":"10.3390\/ijms13089545","volume":"13","author":"M Castells","year":"2012","unstructured":"Castells M, Thibault B, Delord J-P, Couderc B (2012) Implication of tumor microenvironment in chemoresistance: tumor-associated stromal cells protect tumor cells from cell death. Int J Mol Sci 13:9545\u20139571. https:\/\/doi.org\/10.3390\/ijms13089545","journal-title":"Int J Mol Sci"},{"key":"2347_CR16","doi-asserted-by":"publisher","DOI":"10.4137\/cin.s19338","author":"SM Mumenthaler","year":"2015","unstructured":"Mumenthaler SM, Foo J, Choi NC et al (2015) The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells. Cancer Inf https:\/\/doi.org\/10.4137\/cin.s19338","journal-title":"Cancer Inf"},{"key":"2347_CR17","doi-asserted-by":"publisher","first-page":"5113","DOI":"10.3390\/ijms25105113","volume":"25","author":"JY Chan","year":"2024","unstructured":"Chan JY (2024) Special Issue Cancer Immunotherapy: Tumor Microenvironment, Biomarker Discovery and Immune Resistance. Int J Mol Sci 25:5113. https:\/\/doi.org\/10.3390\/ijms25105113","journal-title":"Int J Mol Sci"},{"key":"2347_CR18","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2023.5572","author":"I Lempesis","year":"2023","unstructured":"Lempesis I, Georgakopoulou V, Papalexis P et al (2023) Role of stress in the pathogenesis of cancer (Review). Int J Oncol. https:\/\/doi.org\/10.3892\/ijo.2023.5572","journal-title":"Int J Oncol"},{"key":"2347_CR19","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s13046-022-02519-7","volume":"41","author":"S Schuth","year":"2022","unstructured":"Schuth S, Le Blanc S, Krieger TG et al (2022) Patient-specific modeling of stroma-mediated chemoresistance of pancreatic cancer using a three-dimensional organoid-fibroblast co-culture system. J Exp Clin Cancer Res 41:312. https:\/\/doi.org\/10.1186\/s13046-022-02519-7","journal-title":"J Exp Clin Cancer Res"},{"key":"2347_CR20","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3390\/biom12030367","volume":"12","author":"A Bouyahya","year":"2022","unstructured":"Bouyahya A, Mechchate H, Oumeslakht L et al (2022) The role of epigenetic modifications in human cancers and the use of natural compounds as epidrugs: mechanistic pathways and pharmacodynamic actions. Biomolecules 12:367","journal-title":"Biomolecules"},{"key":"2347_CR21","doi-asserted-by":"publisher","unstructured":"Kaleem M, Azmi L, Shahzad N et al (2025) Epigenetic dynamics and molecular mechanisms in oncogenesis, tumor progression, and therapy resistance. . https:\/\/doi.org\/10.1007\/s00210-025-04217-5","DOI":"10.1007\/s00210-025-04217-5"},{"key":"2347_CR22","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1667\/rr15193.1","volume":"191","author":"CR MacDonald","year":"2019","unstructured":"MacDonald CR, Bucsek MJ, Qiao G et al (2019) Adrenergic receptor signaling regulates the response of tumors to ionizing radiation. Radiat Res 191:585. https:\/\/doi.org\/10.1667\/rr15193.1","journal-title":"Radiat Res"},{"key":"2347_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-022-00818-8","author":"Y Xu","year":"2022","unstructured":"Xu Y, Wang J, Wang X et al (2022) Targeting ADRB2 enhances sensitivity of non-small cell lung cancer to VEGFR2 tyrosine kinase inhibitors. Cell Death Discovery. https:\/\/doi.org\/10.1038\/s41420-022-00818-8","journal-title":"Cell Death Discovery"},{"key":"2347_CR24","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.jare.2024.06.014","volume":"71","author":"H Zhong","year":"2025","unstructured":"Zhong H, Zhou S, Yin S et al (2025) Tumor microenvironment as niche constructed by cancer stem cells: Breaking the ecosystem to combat cancer. J Adv Res 71:279\u2013296. https:\/\/doi.org\/10.1016\/j.jare.2024.06.014","journal-title":"J Adv Res"},{"key":"2347_CR25","unstructured":"Zhoul Y, Shen G, Zhou X, Li J Therapeutic potential of tumor-associated neutrophils: dual role and phenotypic plasticity"},{"key":"2347_CR26","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.3390\/cancers15133327","volume":"15","author":"L Gibellini","year":"2023","unstructured":"Gibellini L, Borella R, Santacroce E et al (2023) Circulating and Tumor-Associated Neutrophils in the Era of Immune Checkpoint Inhibitors: Dynamics, Phenotypes, Metabolism, and Functions. Cancers 15:3327. https:\/\/doi.org\/10.3390\/cancers15133327","journal-title":"Cancers"},{"key":"2347_CR27","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1126\/science.959840","volume":"194","author":"PC Nowell","year":"1976","unstructured":"Nowell PC (1976) The clonal evolution of tumor cell populations: acquired genetic lability permits stepwise selection of variant sublines and underlies tumor progression. Science 194:23\u201328. https:\/\/doi.org\/10.1126\/science.959840","journal-title":"Science"},{"key":"2347_CR28","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00280-019-03840-3","volume":"84","author":"HB Mistry","year":"2019","unstructured":"Mistry HB, Helmlinger G, Al-Huniti N et al (2019) Resistance models to EGFR inhibition and chemotherapy in non-small cell lung cancer via analysis of tumour size dynamics. Cancer Chemother Pharmacol 84:51\u201360. https:\/\/doi.org\/10.1007\/s00280-019-03840-3","journal-title":"Cancer Chemother Pharmacol"},{"key":"2347_CR29","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41586-020-2698-6","volume":"587","author":"TBK Watkins","year":"2020","unstructured":"Watkins TBK, Lim EL, Petkovic M et al (2020) Pervasive chromosomal instability and karyotype order in tumour evolution. Nature 587:126\u2013132. https:\/\/doi.org\/10.1038\/s41586-020-2698-6","journal-title":"Nature"},{"key":"2347_CR30","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1038\/s41467-021-22057-8","volume":"12","author":"T Vaclova","year":"2021","unstructured":"Vaclova T, Grazini U, Ward L et al (2021) Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers. Nat Commun 12:1780","journal-title":"Nat Commun"},{"key":"2347_CR31","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13045-023-01425-5","volume":"16","author":"K Butler","year":"2023","unstructured":"Butler K, Banday AR (2023) APOBEC3-mediated mutagenesis in cancer: causes, clinical significance and therapeutic potential. J Hematol Oncol 16:31. https:\/\/doi.org\/10.1186\/s13045-023-01425-5","journal-title":"J Hematol Oncol"},{"key":"2347_CR32","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41586-022-04972-y","volume":"607","author":"M Petljak","year":"2022","unstructured":"Petljak M, Dananberg A, Chu K et al (2022) Mechanisms of APOBEC3 mutagenesis in human cancer cells. Nature 607:799\u2013807","journal-title":"Nature"},{"key":"2347_CR33","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/CAD.0000000000001707","volume":"36","author":"X Jin","year":"2025","unstructured":"Jin X, Quan Y, Liu J et al (2025) Transformation from acquired EGFR 19del\/C797S to EGFR 19del\/T790M in an advanced non-small cell lung cancer patient: a case report and literature review. Anticancer Drugs 36:513\u2013517. https:\/\/doi.org\/10.1097\/CAD.0000000000001707","journal-title":"Anticancer Drugs"},{"key":"2347_CR34","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1111\/ejh.14107","volume":"111","author":"C Kockerols","year":"2023","unstructured":"Kockerols C, Valk PJM, Blijlevens NMA et al (2023) BCR::ABL1 kinase domain mutation testing and clinical outcome in a nationwide chronic myeloid leukemia patient population. Eur J Haematol 111:938\u2013945. https:\/\/doi.org\/10.1111\/ejh.14107","journal-title":"Eur J Haematol"},{"key":"2347_CR35","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1158\/1078-0432.CCR-24-2307","volume":"31","author":"C-CA Lin","year":"2025","unstructured":"Lin C-CA, Chica-Parrado MR, Unni N et al (2025) ESR1 Y537S and D538G Mutations Drive Resistance to CDK4\/6 Inhibitors in Estrogen Receptor\u2013Positive Breast Cancer. Clin Cancer Res 31:1667\u20131675. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-2307","journal-title":"Clin Cancer Res"},{"key":"2347_CR36","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/cbin.12249","volume":"49","author":"Y Yang","year":"2025","unstructured":"Yang Y, Yang H, Gao Y et al (2025) EML4-ALK G1202R and EML4\u2010ALK L1196M mutations induce crizotinib resistance in non\u2010small cell lung cancer cells through activating epithelial\u2013mesenchymal transition mediated by MDM2\/MEK\/ERK signal axis. Cell Biol Int 49:55\u201367. https:\/\/doi.org\/10.1002\/cbin.12249","journal-title":"Cell Biol Int"},{"key":"2347_CR37","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3390\/biom16010123","volume":"16","author":"A Duminuco","year":"2026","unstructured":"Duminuco A, De Luca P, Stanzione G et al (2026) BTK Inhibition in Hematology: From CLL\/SLL to Emerging Applications Across B-Cell and Immune Disorders. Biomolecules 16:123. https:\/\/doi.org\/10.3390\/biom16010123","journal-title":"Biomolecules"},{"key":"2347_CR38","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1182\/blood.2024026672","volume":"145","author":"CS Tam","year":"2025","unstructured":"Tam CS, Balendran S, Blombery P (2025) Novel mechanisms of resistance in CLL: variant BTK mutations in second-generation and noncovalent BTK inhibitors. Blood 145:1005\u20131009. https:\/\/doi.org\/10.1182\/blood.2024026672","journal-title":"Blood"},{"key":"2347_CR39","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3390\/cancers17030428","volume":"17","author":"M Takeda","year":"2025","unstructured":"Takeda M, Yoshida S, Inoue T et al (2025) The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives. Cancers 17:428. https:\/\/doi.org\/10.3390\/cancers17030428","journal-title":"Cancers"},{"key":"2347_CR40","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1158\/1538-7445.AM2019-954","volume":"79","author":"H Lu","year":"2019","unstructured":"Lu H, Liu C, Velazquez R et al (2019) Abstract 954: SHP2 inhibition overcomes RTK-mediated pathway reactivation in KRAS mutant tumors treated with MEK inhibitors. Cancer Res 79:954\u2013954. https:\/\/doi.org\/10.1158\/1538-7445.AM2019-954","journal-title":"Cancer Res"},{"key":"2347_CR41","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41586-021-04065-2","volume":"599","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Murciano-Goroff YR, Xue JY et al (2021) Diverse alterations associated with resistance to KRAS(G12C) inhibition. Nature 599:679\u2013683. https:\/\/doi.org\/10.1038\/s41586-021-04065-2","journal-title":"Nature"},{"key":"2347_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30881-9","author":"BM Murphy","year":"2022","unstructured":"Murphy BM, Terrell EM, Chirasani VR et al (2022) Enhanced BRAF engagement by NRAS mutants capable of promoting melanoma initiation. Nat Commun. https:\/\/doi.org\/10.1038\/s41467-022-30881-9","journal-title":"Nat Commun"},{"key":"2347_CR43","doi-asserted-by":"publisher","first-page":"1723066","DOI":"10.3389\/fcell.2025.1723066","volume":"13","author":"X Fang","year":"2026","unstructured":"Fang X, Wang S, Fu S (2026) Dissecting the MAPK signaling landscape in malignant melanoma: from BRAF and NRAS mutations to precision combination therapies. Front Cell Dev Biol 13:1723066. https:\/\/doi.org\/10.3389\/fcell.2025.1723066","journal-title":"Front Cell Dev Biol"},{"key":"2347_CR44","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1038\/onc.2015.377","volume":"35","author":"H Cheng","year":"2015","unstructured":"Cheng H, Liu P, Ohlson C et al (2015) PIK3CAH1047R- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling. Oncogene 35:2961\u20132970. https:\/\/doi.org\/10.1038\/onc.2015.377","journal-title":"Oncogene"},{"key":"2347_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-023-02656-3","author":"W Ding","year":"2024","unstructured":"Ding W, Yang P, Zhao X et al (2024) Unraveling EGFR-TKI resistance in lung cancer with high PD-L1 or TMB in EGFR-sensitive mutations. Respir Res. https:\/\/doi.org\/10.1186\/s12931-023-02656-3. 25:","journal-title":"Respir Res"},{"key":"2347_CR46","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1158\/1078-0432.ccr-15-1762","volume":"22","author":"C Krepler","year":"2016","unstructured":"Krepler C, Xiao M, Sproesser K et al (2016) Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies. Clin Cancer Res 22:1592\u20131602. https:\/\/doi.org\/10.1158\/1078-0432.ccr-15-1762","journal-title":"Clin Cancer Res"},{"key":"2347_CR47","doi-asserted-by":"publisher","first-page":"e668","DOI":"10.1016\/j.cllc.2020.11.008","volume":"22","author":"M Metzenmacher","year":"2021","unstructured":"Metzenmacher M, Goetz M, Herold T et al (2021) Acquired Resistance to BRAF\/MEK Inhibitor Therapy in BRAF-V600-mutated Squamous Cell Lung Cancer: Concurrent Evolvement of PTEN and MEK1 Mutations. Clin Lung Cancer 22:e668\u2013e672. https:\/\/doi.org\/10.1016\/j.cllc.2020.11.008","journal-title":"Clin Lung Cancer"},{"key":"2347_CR48","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1158\/1535-7163.mct-22-0302","volume":"22","author":"S Mizuno","year":"2022","unstructured":"Mizuno S, Ikegami M, Koyama T et al (2022) High-Throughput Functional Evaluation of MAP2K1 Variants in Cancer. Mol Cancer Ther 22:227\u2013239. https:\/\/doi.org\/10.1158\/1535-7163.mct-22-0302","journal-title":"Mol Cancer Ther"},{"key":"2347_CR49","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.annonc.2024.01.003","volume":"35","author":"E Harvey-Jones","year":"2024","unstructured":"Harvey-Jones E, Raghunandan M, Robbez-Masson L et al (2024) Longitudinal profiling identifies co-occurring BRCA1\/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer. Ann Oncol 35:364\u2013380. https:\/\/doi.org\/10.1016\/j.annonc.2024.01.003","journal-title":"Ann Oncol"},{"key":"2347_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02048-1","author":"K Nesic","year":"2024","unstructured":"Nesic K, Krais JJ, Wang Y et al (2024) BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance. Mol Cancer. https:\/\/doi.org\/10.1186\/s12943-024-02048-1","journal-title":"Mol Cancer"},{"key":"2347_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1354427","author":"L Collet","year":"2024","unstructured":"Collet L, Hanvic B, Turinetto M et al (2024) BRCA1\/2 alterations and reversion mutations in the area of PARP inhibitors in high grade ovarian cancer: state of the art and forthcoming challenges. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2024.1354427","journal-title":"Front Oncol"},{"key":"2347_CR52","doi-asserted-by":"publisher","unstructured":"Peters TL, Patil T, Le AT et al (2021) Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC.https:\/\/doi.org\/10.1038\/s41698-021-00231-x","DOI":"10.1038\/s41698-021-00231-x"},{"key":"2347_CR53","doi-asserted-by":"publisher","unstructured":"Deng F, Ma W, Wei S (2026) Targeting Mesenchymal-Epidermal Transition (MET) Aberrations in Non-Small Cell Lung Cancer: Current Challenges and Therapeutic Advances. Cancers 18:207. https:\/\/doi.org\/10.3390\/cancers18020207","DOI":"10.3390\/cancers18020207"},{"key":"2347_CR54","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41388-025-03653-0","volume":"45","author":"P Dey","year":"2026","unstructured":"Dey P, Bishnu A, Patel J et al (2026) Hotspot mutations in HER2 interfaces destabilize structure, causing breast cancer treatment failure. Oncogene 45:414\u2013430. https:\/\/doi.org\/10.1038\/s41388-025-03653-0","journal-title":"Oncogene"},{"key":"2347_CR55","doi-asserted-by":"publisher","unstructured":"Sheng T, Sundar R, Srivastava S et al (2025) Spatial profiling of patient-matched HER2 positive gastric cancer reveals resistance mechanisms to targeted therapy. https:\/\/doi.org\/10.1136\/gutjnl-2024-334667. Gut gutjnl-2024-334667","DOI":"10.1136\/gutjnl-2024-334667"},{"key":"2347_CR56","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41419-025-07663-4","volume":"16","author":"F Shao","year":"2025","unstructured":"Shao F, Wang R, Li X et al (2025) TTC36 promotes proliferation and drug resistance in hepatocellular carcinoma cells by inhibiting c-Myc degradation. Cell Death Dis 16:332. https:\/\/doi.org\/10.1038\/s41419-025-07663-4","journal-title":"Cell Death Dis"},{"key":"2347_CR57","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1158\/2159-8290.cd-23-0656","volume":"14","author":"SP Choudhuri","year":"2024","unstructured":"Choudhuri SP, Girard L, Lim JYS et al (2024) Acquired Cross-resistance in Small Cell Lung Cancer due to Extrachromosomal DNA Amplification of MYC paralogs. Cancer Discov 14:804\u2013827. https:\/\/doi.org\/10.1158\/2159-8290.cd-23-0656","journal-title":"Cancer Discov"},{"key":"2347_CR58","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.drup.2017.10.003","volume":"32","author":"I Genovese","year":"2017","unstructured":"Genovese I, Ilari A, Assaraf YG et al (2017) Not only P-glycoprotein: Amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins. Drug Resist Updates 32:23\u201346. https:\/\/doi.org\/10.1016\/j.drup.2017.10.003","journal-title":"Drug Resist Updates"},{"key":"2347_CR59","doi-asserted-by":"publisher","first-page":"9388","DOI":"10.1158\/0008-5472.CAN-04-4133","volume":"65","author":"KG Chen","year":"2005","unstructured":"Chen KG, Wang YC, Schaner ME et al (2005) Genetic and Epigenetic Modeling of the Origins of Multidrug-Resistant Cells in a Human Sarcoma Cell Line. Cancer Res 65:9388\u20139397. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-4133","journal-title":"Cancer Res"},{"key":"2347_CR60","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1182\/blood-2024-211279","volume":"144","author":"V Nardi","year":"2024","unstructured":"Nardi V, Schwieterman J, Kincaid Z et al (2024) A Novel BCR::ABL1 Rearrangement Harboring the Gatekeeper Mutation Drives Hyper-Kinase Activity Conferring Resistance to Ponatinib and Asciminib Combination Therapy. Blood 144:4541\u20134541. https:\/\/doi.org\/10.1182\/blood-2024-211279","journal-title":"Blood"},{"key":"2347_CR61","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1158\/1078-0432.ccr-19-1104","volume":"26","author":"G Recondo","year":"2020","unstructured":"Recondo G, Mezquita L, Facchinetti F et al (2020) Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer. Clin Cancer Res 26:242\u2013255. https:\/\/doi.org\/10.1158\/1078-0432.ccr-19-1104","journal-title":"Clin Cancer Res"},{"key":"2347_CR62","doi-asserted-by":"publisher","first-page":"e240224","DOI":"10.1530\/ERC-24-0224","volume":"32","author":"RJ Clifton-Bligh","year":"2024","unstructured":"Clifton-Bligh RJ (2024) Mechanisms of resistance to RET-directed therapies. Endocrine-related Cancer 32:e240224. https:\/\/doi.org\/10.1530\/ERC-24-0224","journal-title":"Endocrine-related Cancer"},{"key":"2347_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03593-3","author":"C Wang","year":"2022","unstructured":"Wang C, Zhang Z, Sun Y et al (2022) RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer. J Translational Med. https:\/\/doi.org\/10.1186\/s12967-022-03593-3. 20:","journal-title":"J Translational Med"},{"key":"2347_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00563-4","author":"V Subbiah","year":"2024","unstructured":"Subbiah V, Gouda MA, Iorgulescu JB et al (2024) Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer. npj Precision Oncol. https:\/\/doi.org\/10.1038\/s41698-024-00563-4","journal-title":"npj Precision Oncol"},{"key":"2347_CR65","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1111\/cas.16033","volume":"115","author":"K Nakamura","year":"2024","unstructured":"Nakamura K, Hayashi H, Kawano R et al (2024) BRCA1\/2 reversion mutations in a pan-cancer cohort. Cancer Sci 115:635\u2013647. https:\/\/doi.org\/10.1111\/cas.16033","journal-title":"Cancer Sci"},{"key":"2347_CR66","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40246-018-0171-5","volume":"12","author":"FC Cardoso","year":"2018","unstructured":"Cardoso FC, Goncalves S, Mele PG et al (2018) BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population. Hum Genomics 12:39. https:\/\/doi.org\/10.1186\/s40246-018-0171-5","journal-title":"Hum Genomics"},{"key":"2347_CR67","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ejca.2016.04.019","volume":"63","author":"C Mirantes","year":"2016","unstructured":"Mirantes C, Dosil MA, Eritja N et al (2016) Effects of the multikinase inhibitors Sorafenib and Regorafenib in PTEN deficient neoplasias. Eur J Cancer 63:74\u201387. https:\/\/doi.org\/10.1016\/j.ejca.2016.04.019","journal-title":"Eur J Cancer"},{"key":"2347_CR68","doi-asserted-by":"publisher","first-page":"101235","DOI":"10.1016\/j.neo.2025.101235","volume":"70","author":"F Ahmad","year":"2025","unstructured":"Ahmad F, White M, Yamamoto K et al (2025) Metabolic and imaging phenotypes associated with RB1 and TP53 loss in prostate cancer. Neoplasia 70:101235. https:\/\/doi.org\/10.1016\/j.neo.2025.101235","journal-title":"Neoplasia"},{"key":"2347_CR69","doi-asserted-by":"publisher","unstructured":"Chen HJ, Gardner EE, Shah Y et al (2025) Metastatic small cell lung cancer arises from TP53\/RB1-deficient and MYC overproduction hESC-derived PNECs. https:\/\/doi.org\/10.7554\/elife.93170. eLife 13:","DOI":"10.7554\/elife.93170"},{"key":"2347_CR70","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1373\/clinchem.2014.224808","volume":"60","author":"JD Kuhlmann","year":"2014","unstructured":"Kuhlmann JD, Wimberger P, Bankfalvi A et al (2014) ERCC1-Positive Circulating Tumor Cells in the Blood of Ovarian Cancer Patients as a Predictive Biomarker for Platinum Resistance. Clin Chem 60:1282\u20131289. https:\/\/doi.org\/10.1373\/clinchem.2014.224808","journal-title":"Clin Chem"},{"key":"2347_CR71","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2152\/jmi.67.391","volume":"67","author":"DAE Elrawi","year":"2020","unstructured":"Elrawi DAE, khodary AIE, Nassar HR et al (2020) Significance of ERCC1 and Hormonal Receptor Expression in Ovarian Cancer. J Med Invest 67:391\u2013398. https:\/\/doi.org\/10.2152\/jmi.67.391","journal-title":"J Med Invest"},{"key":"2347_CR72","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1177\/1724600820963396","volume":"35","author":"C Zhang","year":"2020","unstructured":"Zhang C, Gao S, Hou J (2020) ERCC1 expression and platinum chemosensitivity in patients with ovarian cancer: A meta-analysis. Int J Biol Markers 35:12\u201319. https:\/\/doi.org\/10.1177\/1724600820963396","journal-title":"Int J Biol Markers"},{"key":"2347_CR73","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/1759-7714.12958","volume":"10","author":"S Takemoto","year":"2019","unstructured":"Takemoto S, Nakamura Y, Gyoutoku H et al (2019) Phase II trial of a non-platinum triplet for patients with advanced non-small cell lung carcinoma (NSCLC) overexpressing ERCC1 messenger RNA. Thorac Cancer 10:452\u2013458. https:\/\/doi.org\/10.1111\/1759-7714.12958","journal-title":"Thorac Cancer"},{"key":"2347_CR74","doi-asserted-by":"publisher","first-page":"14476","DOI":"10.3390\/ijms241914476","volume":"24","author":"J Xu","year":"2023","unstructured":"Xu J, Dai Y, Gao Y et al (2023) RAD51D Secondary Mutation-Mediated Resistance to PARP-Inhibitor-Based Therapy in HGSOC. Int J Mol Sci 24:14476. https:\/\/doi.org\/10.3390\/ijms241914476","journal-title":"Int J Mol Sci"},{"key":"2347_CR75","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1186\/s12967-025-06767-x","volume":"23","author":"M Buonaiuto","year":"2025","unstructured":"Buonaiuto M, Cuomo M, Costabile D et al (2025) DNA methylation remodeling in temozolomide resistant recurrent glioblastoma: comparing epigenetic dynamics in vitro and in vivo. J Transl Med 23:779. https:\/\/doi.org\/10.1186\/s12967-025-06767-x","journal-title":"J Transl Med"},{"key":"2347_CR76","doi-asserted-by":"publisher","first-page":"003685042513450","DOI":"10.1177\/00368504251345014","volume":"108","author":"C Fang","year":"2025","unstructured":"Fang C, Zhang G, Ye S et al (2025) Regulatory mechanisms of O6-methylguanine methyltransferase expression in glioma cells. Sci Prog 108:00368504251345014. https:\/\/doi.org\/10.1177\/00368504251345014","journal-title":"Sci Prog"},{"key":"2347_CR77","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.3390\/biom15071018","volume":"15","author":"G Xu","year":"2025","unstructured":"Xu G, Jiang Y, Sun C et al (2025) Role of Oral Bacteria in Mediating Gemcitabine Resistance in Pancreatic Cancer. Biomolecules 15:1018. https:\/\/doi.org\/10.3390\/biom15071018","journal-title":"Biomolecules"},{"key":"2347_CR78","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1126\/science.aah5043","volume":"357","author":"LT Geller","year":"2017","unstructured":"Geller LT, Barzily-Rokni M, Danino T et al (2017) Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science 357:1156\u20131160. https:\/\/doi.org\/10.1126\/science.aah5043","journal-title":"Science"},{"key":"2347_CR79","doi-asserted-by":"publisher","first-page":"109448","DOI":"10.1016\/j.cbi.2021.109448","volume":"340","author":"J Hofman","year":"2021","unstructured":"Hofman J, Vagiannis D, Chen S, Guo L (2021) Roles of CYP3A4, CYP3A5 and CYP2C8 drug-metabolizing enzymes in cellular cytostatic resistance. Chemico-Biol Interact 340:109448. https:\/\/doi.org\/10.1016\/j.cbi.2021.109448","journal-title":"Chemico-Biol Interact"},{"key":"2347_CR80","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1002\/cncr.34704","volume":"129","author":"G Ghiaur","year":"2023","unstructured":"Ghiaur G, Valkenburg KC, Esteb C et al (2023) Bone marrow niche chemoprotection of metastatic solid tumors mediated by CYP3A4. Cancer 129:1744\u20131751. https:\/\/doi.org\/10.1002\/cncr.34704","journal-title":"Cancer"},{"key":"2347_CR81","doi-asserted-by":"publisher","first-page":"112630","DOI":"10.1016\/j.biopha.2022.112630","volume":"147","author":"J-B Delhorme","year":"2022","unstructured":"Delhorme J-B, Bersuder E, Terciolo C et al (2022) CDX2 controls genes involved in the metabolism of 5-fluorouracil and is associated with reduced efficacy of chemotherapy in colorectal cancer. Biomed Pharmacother 147:112630. https:\/\/doi.org\/10.1016\/j.biopha.2022.112630","journal-title":"Biomed Pharmacother"},{"key":"2347_CR82","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1186\/s12885-016-2826-8","volume":"16","author":"T Kunicka","year":"2016","unstructured":"Kunicka T, Prochazka P, Krus I et al (2016) Molecular profile of 5-fluorouracil pathway genes in colorectal carcinoma. BMC Cancer 16:795. https:\/\/doi.org\/10.1186\/s12885-016-2826-8","journal-title":"BMC Cancer"},{"key":"2347_CR83","doi-asserted-by":"publisher","first-page":"e0252822","DOI":"10.1371\/journal.pone.0252822","volume":"16","author":"T Watanabe","year":"2021","unstructured":"Watanabe T, Oba T, Tanimoto K et al (2021) Tamoxifen resistance alters sensitivity to 5-fluorouracil in a subset of estrogen receptor-positive breast cancer. PLoS ONE 16:e0252822. https:\/\/doi.org\/10.1371\/journal.pone.0252822","journal-title":"PLoS ONE"},{"key":"2347_CR84","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1158\/2159-8290.cd-16-1223","volume":"7","author":"DS Shin","year":"2017","unstructured":"Shin DS, Zaretsky JM, Escuin-Ordinas H et al (2017) Primary Resistance to PD-1 Blockade Mediated by JAK(1\/2) Mutations. Cancer Discov 7:188\u2013201. https:\/\/doi.org\/10.1158\/2159-8290.cd-16-1223","journal-title":"Cancer Discov"},{"key":"2347_CR85","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15440","author":"A Sucker","year":"2017","unstructured":"Sucker A, Zhao F, Pieper N et al (2017) Acquired IFN\u03b3 resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions. Nat Commun. https:\/\/doi.org\/10.1038\/ncomms15440","journal-title":"Nat Commun"},{"key":"2347_CR86","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/nejmoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky JM, Garcia-Diaz A, Shin DS et al (2016) Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N Engl J Med 375:819\u2013829. https:\/\/doi.org\/10.1056\/nejmoa1604958","journal-title":"N Engl J Med"},{"key":"2347_CR87","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1158\/2159-8290.CD-20-0987","volume":"11","author":"G Germano","year":"2021","unstructured":"Germano G, Lu S, Rospo G et al (2021) CD4 T Cell\u2013Dependent Rejection of Beta-2 Microglobulin Null Mismatch Repair\u2013Deficient Tumors. Cancer Discov 11:1844\u20131859. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0987","journal-title":"Cancer Discov"},{"key":"2347_CR88","doi-asserted-by":"publisher","first-page":"1742651","DOI":"10.3389\/fphar.2025.1742651","volume":"16","author":"Q Han","year":"2026","unstructured":"Han Q, Jiang S, Chen J, Xue L (2026) Novel therapeutic strategies targeting resistance mechanisms in hematologic malignancies: from BCL2 inhibition to immunomodulatory approaches. Front Pharmacol 16:1742651. https:\/\/doi.org\/10.3389\/fphar.2025.1742651","journal-title":"Front Pharmacol"},{"key":"2347_CR89","doi-asserted-by":"publisher","first-page":"3333","DOI":"10.1111\/cas.16292","volume":"115","author":"Y Matsui","year":"2024","unstructured":"Matsui Y, Yamada T, Katayama Y et al (2024) Initial AXL and MCL-1 inhibition contributes to abolishing lazertinib tolerance in EGFR\u2010mutant lung cancer cells. Cancer Sci 115:3333\u20133345. https:\/\/doi.org\/10.1111\/cas.16292","journal-title":"Cancer Sci"},{"key":"2347_CR90","doi-asserted-by":"publisher","first-page":"e71390","DOI":"10.1002\/hsr2.71390","volume":"8","author":"M Mohiuddin","year":"2025","unstructured":"Mohiuddin M (2025) Targeting MCL-1 to Overcome Therapeutic Resistance and Improve Cancer Mortality. Health Sci Rep 8:e71390. https:\/\/doi.org\/10.1002\/hsr2.71390","journal-title":"Health Sci Rep"},{"key":"2347_CR91","doi-asserted-by":"publisher","first-page":"6209","DOI":"10.1111\/febs.16136","volume":"289","author":"M Sancho","year":"2022","unstructured":"Sancho M, Leiva D, Lucendo E, Orz\u00e1ez M (2022) Understanding MCL1: from cellular function and regulation to pharmacological inhibition. FEBS J 289:6209\u20136234. https:\/\/doi.org\/10.1111\/febs.16136","journal-title":"FEBS J"},{"key":"2347_CR92","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s41061-025-00505-z","volume":"383","author":"Z Shafaghat","year":"2025","unstructured":"Shafaghat Z, Radmehr S, Saharkhiz S et al (2025) Circular RNA, a molecule with potential chemistry and applications in RNA-based cancer therapeutics: an insight into recent advances. Top Curr Chem 383:21. https:\/\/doi.org\/10.1007\/s41061-025-00505-z","journal-title":"Top Curr Chem"},{"key":"2347_CR93","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.2147\/DDDT.S448707","volume":"18","author":"J Zhang","year":"2024","unstructured":"Zhang J, Wu L, Wang C et al (2024) Research progress of long non-coding RNA in tumor drug resistance: a new paradigm. Drug Des Dev Ther Volume 18:1385\u20131398. https:\/\/doi.org\/10.2147\/DDDT.S448707","journal-title":"Drug Des Dev Ther Volume"},{"key":"2347_CR94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ijo.2025.5741","volume":"66","author":"J Li","year":"2025","unstructured":"Li J, Li Y, Fu L et al (2025) Targeting ncRNAs to overcome metabolic reprogramming\u2013mediated drug resistance in cancer (Review). Int J Oncol 66:1\u201329. https:\/\/doi.org\/10.3892\/ijo.2025.5741","journal-title":"Int J Oncol"},{"key":"2347_CR95","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13578-018-0260-0","volume":"8","author":"C Xu","year":"2018","unstructured":"Xu C, Guo Y, Liu H et al (2018) TUG1 confers cisplatin resistance in esophageal squamous cell carcinoma by epigenetically suppressing PDCD4 expression via EZH2. Cell Biosci 8:61. https:\/\/doi.org\/10.1186\/s13578-018-0260-0","journal-title":"Cell Biosci"},{"key":"2347_CR96","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nature05913","volume":"447","author":"A Bird","year":"2007","unstructured":"Bird A (2007) Perceptions of epigenetics. Nature 447:396\u2013398. https:\/\/doi.org\/10.1038\/nature05913","journal-title":"Nature"},{"key":"2347_CR97","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13578-019-0278-y","volume":"9","author":"Y Luo","year":"2019","unstructured":"Luo Y, Huang J, Tang Y et al (2019) Regional methylome profiling reveals dynamic epigenetic heterogeneity and convergent hypomethylation of stem cell quiescence-associated genes in breast cancer following neoadjuvant chemotherapy. Cell Biosci 9:16. https:\/\/doi.org\/10.1186\/s13578-019-0278-y","journal-title":"Cell Biosci"},{"key":"2347_CR98","doi-asserted-by":"publisher","first-page":"8721","DOI":"10.7150\/thno.41648","volume":"10","author":"T Huang","year":"2020","unstructured":"Huang T, Song X, Xu D et al (2020) Stem cell programs in cancer initiation, progression, and therapy resistance. Theranostics 10:8721\u20138743. https:\/\/doi.org\/10.7150\/thno.41648","journal-title":"Theranostics"},{"key":"2347_CR99","doi-asserted-by":"publisher","first-page":"103924","DOI":"10.1016\/j.isci.2022.103924","volume":"25","author":"A Shomar","year":"2022","unstructured":"Shomar A, Barak O, Brenner N (2022) Cancer progression as a learning process. Iscience 25:103924. https:\/\/doi.org\/10.1016\/j.isci.2022.103924","journal-title":"Iscience"},{"key":"2347_CR100","doi-asserted-by":"publisher","first-page":"1177466","DOI":"10.3389\/fonc.2023.1177466","volume":"13","author":"X-W Liang","year":"2023","unstructured":"Liang X-W, Liu B-, Chen J-C et al (2023) Characteristics and molecular mechanism of drug-tolerant cells in cancer: a review. Front Oncol 13:1177466. https:\/\/doi.org\/10.3389\/fonc.2023.1177466","journal-title":"Front Oncol"},{"key":"2347_CR101","doi-asserted-by":"publisher","first-page":"4417","DOI":"10.1242\/jcs.099697","volume":"125","author":"RY-J Huang","year":"2012","unstructured":"Huang RY-J, Guilford P, Thiery JP (2012) Early events in cell adhesion and polarity during epithelial-mesenchymal transition. J Cell Sci 125:4417\u20134422. https:\/\/doi.org\/10.1242\/jcs.099697","journal-title":"J Cell Sci"},{"key":"2347_CR102","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/cdd.2010.119","volume":"18","author":"M-P Puiss\u00e9gur","year":"2010","unstructured":"Puiss\u00e9gur M-P, Mazure NM, Bertero T et al (2010) miR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity. Cell Death Differ 18:465\u2013478. https:\/\/doi.org\/10.1038\/cdd.2010.119","journal-title":"Cell Death Differ"},{"key":"2347_CR103","doi-asserted-by":"publisher","first-page":"753","DOI":"10.3389\/fonc.2019.00753","volume":"9","author":"HR Walsh","year":"2019","unstructured":"Walsh HR, Cruickshank BM, Brown JM, Marcato P (2019) The flick of a switch: conferring survival advantage to breast cancer stem cells through metabolic plasticity. Front Oncol 9:753. https:\/\/doi.org\/10.3389\/fonc.2019.00753","journal-title":"Front Oncol"},{"key":"2347_CR104","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1038\/nm.3336","volume":"19","author":"WL Tam","year":"2013","unstructured":"Tam WL, Weinberg RA (2013) The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med 19:1438\u20131449. https:\/\/doi.org\/10.1038\/nm.3336","journal-title":"Nat Med"},{"key":"2347_CR105","doi-asserted-by":"publisher","first-page":"955166","DOI":"10.3389\/fonc.2022.955166","volume":"12","author":"R Su","year":"2022","unstructured":"Su R, Chen L, Jiang Z et al (2022) Comprehensive analysis of androgen receptor status in prostate cancer with neuroendocrine differentiation. Front Oncol 12:955166","journal-title":"Front Oncol"},{"key":"2347_CR106","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/s41374-019-0343-5","volume":"100","author":"H Li","year":"2020","unstructured":"Li H, Wang L, Li Z et al (2020) SOX2 has dual functions as a regulator in the progression of neuroendocrine prostate cancer. Lab Invest 100:570\u2013582","journal-title":"Lab Invest"},{"key":"2347_CR107","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1002\/ijc.32430","volume":"145","author":"M Alshalalfa","year":"2019","unstructured":"Alshalalfa M, Liu Y, Wyatt AW et al (2019) Characterization of transcriptomic signature of primary prostate cancer analogous to prostatic small cell neuroendocrine carcinoma. Int J Cancer 145:3453\u20133461. https:\/\/doi.org\/10.1002\/ijc.32430","journal-title":"Int J Cancer"},{"key":"2347_CR108","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/iub.1335","volume":"66","author":"ASL Chan","year":"2014","unstructured":"Chan ASL, Mowla SN, Arora P, Jat PS (2014) Tumour suppressors and cellular senescence. IUBMB Life 66:812\u2013822. https:\/\/doi.org\/10.1002\/iub.1335","journal-title":"IUBMB Life"},{"key":"2347_CR109","doi-asserted-by":"publisher","first-page":"7575","DOI":"10.3390\/ijms22147575","volume":"22","author":"JY-F Chung","year":"2021","unstructured":"Chung JY-F, Chan MK-K, Li JS-F et al (2021) TGF-\u03b2 signaling: from tissue fibrosis to tumor microenvironment. Int J Mol Sci 22:7575. https:\/\/doi.org\/10.3390\/ijms22147575","journal-title":"Int J Mol Sci"},{"key":"2347_CR110","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s43556-022-00109-9","volume":"3","author":"Y Tie","year":"2022","unstructured":"Tie Y, Tang F, Peng D et al (2022) TGF-beta signal transduction: biology, function and therapy for diseases. Mol Biomed 3:45. https:\/\/doi.org\/10.1186\/s43556-022-00109-9","journal-title":"Mol Biomed"},{"key":"2347_CR111","doi-asserted-by":"publisher","first-page":"7851","DOI":"10.2147\/ott.s253485","volume":"13","author":"F Li","year":"2020","unstructured":"Li F, Zhan L, Dong Q et al (2020) Tumor-derived exosome-educated hepatic stellate cells regulate lactate metabolism of hypoxic colorectal tumor cells via the IL-6\/STAT3 pathway to confer drug resistance. OncoTargets Ther Volume 13:7851\u20137864. https:\/\/doi.org\/10.2147\/ott.s253485","journal-title":"OncoTargets Ther Volume"},{"key":"2347_CR112","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.3390\/ijms19051532","volume":"19","author":"T Alkasalias","year":"2018","unstructured":"Alkasalias T, Moyano-Galceran L, Arsenian-Henriksson M, Lehti K (2018) Fibroblasts in the tumor microenvironment: shield or spear? Int J Mol Sci 19:1532","journal-title":"Int J Mol Sci"},{"key":"2347_CR113","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3892\/ol.2021.12798","volume":"22","author":"X Ren","year":"2021","unstructured":"Ren X, Li L, Wu J et al (2021) PDGF\u2013BB regulates the transformation of fibroblasts into cancer\u2013associated fibroblasts via the lncRNA LURAP1L\u2013AS1\/LURAP1L\/IKK\/I\u03baB\/NF\u2013\u03baB signaling pathway. Oncol Lett 22:537. https:\/\/doi.org\/10.3892\/ol.2021.12798","journal-title":"Oncol Lett"},{"key":"2347_CR114","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1038\/s12276-023-01013-0","volume":"55","author":"D Yang","year":"2023","unstructured":"Yang D, Liu J, Qian H, Zhuang Q (2023) Cancer-associated fibroblasts: from basic science to anticancer therapy. Exp Mol Med 55:1322\u20131332","journal-title":"Exp Mol Med"},{"key":"2347_CR115","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.ccell.2023.05.016","volume":"41","author":"H Wang","year":"2023","unstructured":"Wang H, Li N, Liu Q et al (2023) Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer. Cancer Cell 41:1345\u20131362e9. https:\/\/doi.org\/10.1016\/j.ccell.2023.05.016","journal-title":"Cancer Cell"},{"key":"2347_CR116","doi-asserted-by":"publisher","first-page":"8997","DOI":"10.1038\/s41467-024-53093-9","volume":"15","author":"Z Wang","year":"2024","unstructured":"Wang Z, Zhang Q, Jiang Y et al (2024) ASI-RIM neuronal axis regulates systemic mitochondrial stress response via TGF-\u03b2 signaling cascade. Nat Commun 15:8997","journal-title":"Nat Commun"},{"key":"2347_CR117","first-page":"2081","volume":"39","author":"L Wang","year":"2018","unstructured":"Wang L, Zhang F, Cui J-Y et al (2018) CAFs enhance paclitaxel resistance by inducing EMT through the IL-6\/JAK2\/STAT3 pathway. Oncol Rep 39:2081\u20132090","journal-title":"Oncol Rep"},{"key":"2347_CR118","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-025-01924-1","author":"Z Zhao","year":"2025","unstructured":"Zhao Z, Li Q, Qu C et al (2025) A collagenase nanogel backpack improves CAR-T cell therapy outcomes in pancreatic cancer. Nat Nanotechnol. https:\/\/doi.org\/10.1038\/s41565-025-01924-1","journal-title":"Nat Nanotechnol"},{"key":"2347_CR119","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70319","author":"X Wu","year":"2025","unstructured":"Wu X, Jin Z, Li B (2025) Deciphering of intra-tumoural heterogeneity and the interplay between metastasis-associated meta-program and myofibroblasts in gastric cancer. Clin Transl Med. https:\/\/doi.org\/10.1002\/ctm2.70319","journal-title":"Clin Transl Med"},{"key":"2347_CR120","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57465-7","author":"J Song","year":"2025","unstructured":"Song J, Wei R, Liu C et al (2025) Antigen-presenting cancer associated fibroblasts enhance antitumor immunity and predict immunotherapy response. Nat Commun. https:\/\/doi.org\/10.1038\/s41467-025-57465-7","journal-title":"Nat Commun"},{"key":"2347_CR121","doi-asserted-by":"publisher","first-page":"eadj5705","DOI":"10.1126\/scitranslmed.adj5705","volume":"16","author":"G Fan","year":"2024","unstructured":"Fan G, Yu B, Tang L et al (2024) TSPAN8+ myofibroblastic cancer\u2013associated fibroblasts promote chemoresistance in patients with breast cancer. Sci Transl Med 16:eadj5705. https:\/\/doi.org\/10.1126\/scitranslmed.adj5705","journal-title":"Sci Transl Med"},{"key":"2347_CR122","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3390\/cancers13040601","volume":"13","author":"M Amrutkar","year":"2021","unstructured":"Amrutkar M, Gladhaug IP (2021) Stellate cells aid growth-permissive metabolic reprogramming and promote gemcitabine chemoresistance in pancreatic cancer. Cancers 13:601. https:\/\/doi.org\/10.3390\/cancers13040601","journal-title":"Cancers"},{"key":"2347_CR123","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.3390\/cells11192952","volume":"11","author":"D Deng","year":"2022","unstructured":"Deng D, Patel R, Chiang C-Y, Hou P (2022) Role of the tumor microenvironment in regulating pancreatic cancer therapy resistance. Cells 11:2952. https:\/\/doi.org\/10.3390\/cells11192952","journal-title":"Cells"},{"key":"2347_CR124","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.3390\/cancers7040902","volume":"7","author":"K Shiga","year":"2015","unstructured":"Shiga K, Hara M, Nagasaki T et al (2015) Cancer-associated fibroblasts: their characteristics and their roles in tumor growth. Cancers 7:2443\u20132458. https:\/\/doi.org\/10.3390\/cancers7040902","journal-title":"Cancers"},{"key":"2347_CR125","doi-asserted-by":"crossref","unstructured":"Marusyk A, Desai B, Miti T et al (2025) Multifactorial stroma-mediated resistance is a major contributor to residual disease under targeted therapies in lung cancers","DOI":"10.21203\/rs.3.rs-6264377\/v1"},{"key":"2347_CR126","doi-asserted-by":"publisher","unstructured":"Zhao L, Ni Y, Ma X et al (2016) A panel of free fatty acid ratios to predict the development of metabolic abnormalities in healthy obese individuals. Sci Rep. https:\/\/doi.org\/10.1038\/srep28418","DOI":"10.1038\/srep28418"},{"key":"2347_CR127","doi-asserted-by":"publisher","first-page":"1634413","DOI":"10.3389\/fphar.2025.1634413","volume":"16","author":"F Chen","year":"2025","unstructured":"Chen F, Fu Y, Bai G et al (2025) Multi-omics dissection of tumor microenvironment-mediated drug resistance: mechanisms and therapeutic reprogramming. Front Pharmacol 16:1634413. https:\/\/doi.org\/10.3389\/fphar.2025.1634413","journal-title":"Front Pharmacol"},{"key":"2347_CR128","doi-asserted-by":"publisher","first-page":"6403","DOI":"10.1016\/j.csbj.2022.11.025","volume":"20","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Mei S, Huang Y et al (2022) Integrative analysis deciphers the heterogeneity of cancer-associated fibroblast and implications on clinical outcomes in ovarian cancers. Comput Struct Biotechnol J 20:6403\u20136411. https:\/\/doi.org\/10.1016\/j.csbj.2022.11.025","journal-title":"Comput Struct Biotechnol J"},{"key":"2347_CR129","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3390\/molecules29020531","volume":"29","author":"X Zhou","year":"2024","unstructured":"Zhou X, Su M, Lu J et al (2024) CD36: the bridge between lipids and tumors. Molecules 29:531. https:\/\/doi.org\/10.3390\/molecules29020531","journal-title":"Molecules"},{"key":"2347_CR130","doi-asserted-by":"publisher","first-page":"4522","DOI":"10.7150\/jca.30989","volume":"10","author":"W-H Xu","year":"2019","unstructured":"Xu W-H, Qu Y-Y, Wang J et al (2019) Elevated CD36 expression correlates with increased visceral adipose tissue and predicts poor prognosis in ccRCC patients. J Cancer 10:4522\u20134531. https:\/\/doi.org\/10.7150\/jca.30989","journal-title":"J Cancer"},{"key":"2347_CR131","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40170-016-0163-7","volume":"5","author":"S Balaban","year":"2017","unstructured":"Balaban S, Shearer RF, Lee LS et al (2017) Adipocyte lipolysis links obesity to breast cancer growth: adipocyte-derived fatty acids drive breast cancer cell proliferation and migration. Cancer Metab 5:1. https:\/\/doi.org\/10.1186\/s40170-016-0163-7","journal-title":"Cancer Metab"},{"key":"2347_CR132","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.3892\/or.2017.5864","volume":"38","author":"J Zhao","year":"2017","unstructured":"Zhao J, Zhi Z, Wang C et al (2017) Exogenous lipids promote the growth of breast cancer cells via CD36. Oncol Rep 38:2105\u20132115. https:\/\/doi.org\/10.3892\/or.2017.5864","journal-title":"Oncol Rep"},{"key":"2347_CR133","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01302-1","author":"SU Khan","year":"2024","unstructured":"Khan SU, Fatima K, Aisha S, Malik F (2024) Unveiling the mechanisms and challenges of cancer drug resistance. Cell Commun Signal. https:\/\/doi.org\/10.1186\/s12964-023-01302-1. 22:","journal-title":"Cell Commun Signal"},{"key":"2347_CR134","doi-asserted-by":"publisher","first-page":"148","DOI":"10.20517\/evcna.2021.06","volume":"2","author":"T Tamura","year":"2021","unstructured":"Tamura T, Yoshioka Y, Sakamoto S et al (2021) Extracellular vesicles as a promising biomarker resource in liquid biopsy for cancer. Extracell Vesicles Circ Nucleic Acids 2:148\u2013174. https:\/\/doi.org\/10.20517\/evcna.2021.06","journal-title":"Extracell Vesicles Circ Nucleic Acids"},{"key":"2347_CR135","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-024-00993-3","author":"S Ye","year":"2024","unstructured":"Ye S, Chen S, Yang X, Lei X (2024) Drug resistance in breast cancer is based on the mechanism of exocrine non-coding RNA. Discov Oncol. https:\/\/doi.org\/10.1007\/s12672-024-00993-3","journal-title":"Discov Oncol"},{"key":"2347_CR136","doi-asserted-by":"publisher","first-page":"112","DOI":"10.20517\/evcna.2024.90","volume":"6","author":"MC Ciferri","year":"2025","unstructured":"Ciferri MC, Tasso R (2025) Extracellular vesicle-mediated chemoresistance in breast cancer: focus on miRNA cargo. Extracell Vesicles Circ Nucleic Acids 6:112\u2013127. https:\/\/doi.org\/10.20517\/evcna.2024.90","journal-title":"Extracell Vesicles Circ Nucleic Acids"},{"key":"2347_CR137","doi-asserted-by":"publisher","first-page":"37151","DOI":"10.18632\/oncotarget.6022","volume":"6","author":"S Yu","year":"2015","unstructured":"Yu S, Cao H, Shen B, Feng J (2015) Tumor-derived exosomes in cancer progression and treatment failure. Oncotarget 6:37151\u201337168. https:\/\/doi.org\/10.18632\/oncotarget.6022","journal-title":"Oncotarget"},{"key":"2347_CR138","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12943-019-1019-x","volume":"18","author":"JL Hu","year":"2019","unstructured":"Hu JL, Wang W, Lan XL et al (2019) CAFs secreted exosomes promote metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in colorectal cancer. Mol Cancer 18:91. https:\/\/doi.org\/10.1186\/s12943-019-1019-x","journal-title":"Mol Cancer"},{"key":"2347_CR139","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1378302","author":"Z Gou","year":"2024","unstructured":"Gou Z, Li J, Liu J, Yang N (2024) The hidden messengers: cancer associated fibroblasts\u2014derived exosomal miRNAs as key regulators of cancer malignancy. Front Cell Dev Biol. https:\/\/doi.org\/10.3389\/fcell.2024.1378302","journal-title":"Front Cell Dev Biol"},{"key":"2347_CR140","doi-asserted-by":"publisher","first-page":"e1792","DOI":"10.1038\/cddis.2015.162","volume":"6","author":"Y Jiang","year":"2015","unstructured":"Jiang Y, Li Y, Zhu B (2015) T-cell exhaustion in the tumor microenvironment. Cell Death Dis 6:e1792\u2013e1792. https:\/\/doi.org\/10.1038\/cddis.2015.162","journal-title":"Cell Death Dis"},{"key":"2347_CR141","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/ni.2703","volume":"14","author":"TF Gajewski","year":"2013","unstructured":"Gajewski TF, Schreiber H, Fu Y-X (2013) Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 14:1014\u20131022. https:\/\/doi.org\/10.1038\/ni.2703","journal-title":"Nat Immunol"},{"key":"2347_CR142","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s40364-024-00646-1","volume":"12","author":"H Zhang","year":"2024","unstructured":"Zhang H, Li S, Wang D et al (2024) Metabolic reprogramming and immune evasion: the interplay in the tumor microenvironment. Biomark Res 12:96. https:\/\/doi.org\/10.1186\/s40364-024-00646-1","journal-title":"Biomark Res"},{"key":"2347_CR143","doi-asserted-by":"publisher","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","volume":"30","author":"NM Anderson","year":"2020","unstructured":"Anderson NM, Simon MC (2020) The tumor microenvironment. Curr Biol 30:R921\u2013R925. https:\/\/doi.org\/10.1016\/j.cub.2020.06.081","journal-title":"Curr Biol"},{"key":"2347_CR144","doi-asserted-by":"publisher","first-page":"490","DOI":"10.3389\/fimmu.2020.00490","volume":"11","author":"L Gibellini","year":"2020","unstructured":"Gibellini L, Biasi SD, Porta C et al (2020) Single-cell approaches to profile the response to immune checkpoint inhibitors. Front Immunol 11:490. https:\/\/doi.org\/10.3389\/fimmu.2020.00490","journal-title":"Front Immunol"},{"key":"2347_CR145","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2020.548719","author":"T Guo","year":"2020","unstructured":"Guo T, Li W, Cai X (2020) Applications of single-cell omics to dissect tumor microenvironment. Front Genet. https:\/\/doi.org\/10.3389\/fgene.2020.548719. 11:","journal-title":"Front Genet"},{"key":"2347_CR146","doi-asserted-by":"publisher","first-page":"3878","DOI":"10.1158\/1538-7445.AM2024-3878","volume":"84","author":"J Cao","year":"2024","unstructured":"Cao J, Shiau C, Gong D et al (2024) Abstract 3878: Therapy-associated remodeling of pancreatic cancer revealed by single-cell spatial transcriptomics and optimal transport analysis. Cancer Res 84:3878\u20133878. https:\/\/doi.org\/10.1158\/1538-7445.AM2024-3878","journal-title":"Cancer Res"},{"key":"2347_CR147","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2024.5684","author":"Y Liu","year":"2024","unstructured":"Liu Y, Liang J, Zhang Y, Guo Q (2024) Drug resistance and tumor immune microenvironment: an overview of current understandings (review). Int J Oncol. https:\/\/doi.org\/10.3892\/ijo.2024.5684","journal-title":"Int J Oncol"},{"key":"2347_CR148","doi-asserted-by":"publisher","first-page":"4","DOI":"10.5966\/sctm.2014-0262","volume":"4","author":"S Talib","year":"2014","unstructured":"Talib S, Millan MT, Jorgenson RL, Shepard KA (2014) Proceedings: immune tolerance and stem cell transplantation: a CIRM mini-symposium and workshop report. Stem Cells Transl Med. 4:4\u20139. https:\/\/doi.org\/10.5966\/sctm.2014-0262","journal-title":"Stem Cells Transl Med"},{"key":"2347_CR149","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01473-w","author":"K Zhou","year":"2022","unstructured":"Zhou K, Nguyen R, Qiao L, George J (2022) Single cell RNA-seq analysis identifies a noncoding RNA mediating resistance to sorafenib treatment in HCC. Mol Cancer. https:\/\/doi.org\/10.1186\/s12943-021-01473-w","journal-title":"Mol Cancer"},{"key":"2347_CR150","doi-asserted-by":"publisher","first-page":"170014","DOI":"10.1098\/rsos.170014","volume":"4","author":"ME Hubbard","year":"2017","unstructured":"Hubbard ME, Jove M, Loadman PM et al (2017) Drug delivery in a tumour cord model: a computational simulation. R Soc Open Sci 4:170014. https:\/\/doi.org\/10.1098\/rsos.170014","journal-title":"R Soc Open Sci"},{"key":"2347_CR151","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1291530","author":"C Qian","year":"2023","unstructured":"Qian C, Liu C, Liu W et al (2023) Targeting vascular normalization: a promising strategy to improve immune\u2013vascular crosstalk in cancer immunotherapy. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2023.1291530","journal-title":"Front Immunol"},{"key":"2347_CR152","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.7150\/thno.103636","volume":"15","author":"X Shao","year":"2025","unstructured":"Shao X, Zhao X, Wang B et al (2025) Tumor microenvironment targeted nano-drug delivery systems for multidrug resistant tumor therapy. Theranostics 15:1689\u20131714. https:\/\/doi.org\/10.7150\/thno.103636","journal-title":"Theranostics"},{"key":"2347_CR153","doi-asserted-by":"publisher","first-page":"100024","DOI":"10.1016\/j.xpro.2020.100024","volume":"1","author":"C Karamboulas","year":"2020","unstructured":"Karamboulas C, Meens J, Ailles L (2020) Establishment and Use of Patient-Derived Xenograft Models for Drug Testing in Head and Neck Squamous Cell Carcinoma. STAR Protocols 1:100024. https:\/\/doi.org\/10.1016\/j.xpro.2020.100024","journal-title":"STAR Protocols"},{"key":"2347_CR154","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.641469","author":"P Wu","year":"2021","unstructured":"Wu P, Gao W, Su M et al (2021) Adaptive mechanisms of tumor therapy resistance driven by tumor microenvironment. Front Cell Dev Biol. https:\/\/doi.org\/10.3389\/fcell.2021.641469","journal-title":"Front Cell Dev Biol"},{"key":"2347_CR155","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.jconrel.2015.08.017","volume":"219","author":"L Miao","year":"2015","unstructured":"Miao L, Lin CM, Huang L (2015) Stromal barriers and strategies for the delivery of nanomedicine to desmoplastic tumors. J Controlled Release 219:192\u2013204. https:\/\/doi.org\/10.1016\/j.jconrel.2015.08.017","journal-title":"J Controlled Release"},{"key":"2347_CR156","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1039\/C8LC00970H","volume":"19","author":"M Shang","year":"2019","unstructured":"Shang M, Soon RH, Lim CT et al (2019) Microfluidic modelling of the tumor microenvironment for anti-cancer drug development. Lab Chip 19:369\u2013386. https:\/\/doi.org\/10.1039\/C8LC00970H","journal-title":"Lab Chip"},{"key":"2347_CR157","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3390\/jpm11020124","volume":"11","author":"D Huang","year":"2021","unstructured":"Huang D, Sun L, Huang L, Chen Y (2021) Nanodrug delivery systems modulate tumor vessels to increase the enhanced permeability and retention effect. J Pers Med 11:124. https:\/\/doi.org\/10.3390\/jpm11020124","journal-title":"J Pers Med"},{"key":"2347_CR158","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-04297-y","author":"MJ Al-khreisat","year":"2025","unstructured":"Al-khreisat MJ, Abdulsahib WK, Jasim IK et al (2025) Targeting cancer stem cell plasticity and tumor microenvironment crosstalk: a comprehensive review. Discov Oncol. https:\/\/doi.org\/10.1007\/s12672-025-04297-y","journal-title":"Discov Oncol"},{"key":"2347_CR159","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/S0006-2952(03)00467-2","volume":"66","author":"BP Mahoney","year":"2003","unstructured":"Mahoney BP, Raghunand N, Baggett B, Gillies RJ (2003) Tumor acidity, ion trapping and chemotherapeutics. Biochem Pharmacol 66:1207\u20131218. https:\/\/doi.org\/10.1016\/S0006-2952(03)00467-2","journal-title":"Biochem Pharmacol"},{"key":"2347_CR160","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/nrd3554","volume":"10","author":"D Neri","year":"2011","unstructured":"Neri D, Supuran CT (2011) Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov 10:767\u2013777. https:\/\/doi.org\/10.1038\/nrd3554","journal-title":"Nat Rev Drug Discov"},{"key":"2347_CR161","doi-asserted-by":"publisher","first-page":"488","DOI":"10.3390\/ijms23010488","volume":"23","author":"A Sevcikova","year":"2022","unstructured":"Sevcikova A, Izoldova N, Stevurkova V et al (2022) The Impact of the Microbiome on Resistance to Cancer Treatment with Chemotherapeutic Agents and Immunotherapy. Int J Mol Sci 23:488. https:\/\/doi.org\/10.3390\/ijms23010488","journal-title":"Int J Mol Sci"},{"key":"2347_CR162","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1007\/s12094-022-02919-3","volume":"24","author":"L Liu","year":"2022","unstructured":"Liu L, Bai Y, Xiang L et al (2022) Interaction between gut microbiota and tumour chemotherapy. Clin Transl Oncol 24:2330\u20132341. https:\/\/doi.org\/10.1007\/s12094-022-02919-3","journal-title":"Clin Transl Oncol"},{"key":"2347_CR163","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1007\/s12672-025-03574-0","volume":"16","author":"Z Sadeghloo","year":"2025","unstructured":"Sadeghloo Z, Sadeghi A (2025) Gut microbiota as a hidden modulator of chemotherapy: implications for colorectal cancer treatment. Discov Onc 16:1717. https:\/\/doi.org\/10.1007\/s12672-025-03574-0","journal-title":"Discov Onc"},{"key":"2347_CR164","doi-asserted-by":"publisher","first-page":"2295384","DOI":"10.1080\/19490976.2023.2295384","volume":"16","author":"C Martin-Gallausiaux","year":"2024","unstructured":"Martin-Gallausiaux C, Salesse L, Garcia-Weber D et al (2024) Fusobacterium nucleatum promotes inflammatory and anti-apoptotic responses in colorectal cancer cells via ADP-heptose release and ALPK1\/TIFA axis activation. Gut Microbes 16:2295384. https:\/\/doi.org\/10.1080\/19490976.2023.2295384","journal-title":"Gut Microbes"},{"key":"2347_CR165","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1126\/science.1240527","volume":"342","author":"N Iida","year":"2013","unstructured":"Iida N, Dzutsev A, Stewart CA et al (2013) Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 342:967\u2013970. https:\/\/doi.org\/10.1126\/science.1240527","journal-title":"Science"},{"key":"2347_CR166","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1159\/000508675","volume":"15","author":"AD Hartkopf","year":"2020","unstructured":"Hartkopf AD, Grischke E-M, Brucker SY (2020) Endocrine-Resistant Breast Cancer: Mechanisms and Treatment. Breast Care 15:347\u2013354. https:\/\/doi.org\/10.1159\/000508675","journal-title":"Breast Care"},{"key":"2347_CR167","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s12609-011-0065-1","volume":"4","author":"M Khasraw","year":"2012","unstructured":"Khasraw M, Harvey SL, Bell R (2012) Hormonal Resistance in Breast Cancer: Evolving Treatment Strategies. Curr Breast Cancer Rep 4:66\u201374. https:\/\/doi.org\/10.1007\/s12609-011-0065-1","journal-title":"Curr Breast Cancer Rep"},{"key":"2347_CR168","doi-asserted-by":"publisher","first-page":"573","DOI":"10.3389\/fendo.2019.00573","volume":"10","author":"MM Haque","year":"2019","unstructured":"Haque MM, Desai KV (2019) Pathways to endocrine therapy resistance in breast cancer. Front Endocrinol 10:573. https:\/\/doi.org\/10.3389\/fendo.2019.00573","journal-title":"Front Endocrinol"},{"key":"2347_CR169","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13045-020-00904-3","volume":"13","author":"H Hua","year":"2020","unstructured":"Hua H, Kong Q, Yin J et al (2020) Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy. J Hematol Oncol 13:64. https:\/\/doi.org\/10.1186\/s13045-020-00904-3","journal-title":"J Hematol Oncol"},{"key":"2347_CR170","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.3390\/cancers11121894","volume":"11","author":"ID Santo","year":"2019","unstructured":"Santo ID, McCartney A, Migliaccio I et al (2019) The emerging role of ESR1 mutations in luminal breast cancer as a prognostic and predictive biomarker of response to endocrine therapy. Cancers 11:1894. https:\/\/doi.org\/10.3390\/cancers11121894","journal-title":"Cancers"},{"key":"2347_CR171","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/aps.2012.72","volume":"33","author":"I Pal","year":"2012","unstructured":"Pal I, Mandal M (2012) PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes. Acta Pharmacol Sin 33:1441\u20131458. https:\/\/doi.org\/10.1038\/aps.2012.72","journal-title":"Acta Pharmacol Sin"},{"key":"2347_CR172","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.615375","author":"T Scully","year":"2021","unstructured":"Scully T, Ettela A, LeRoith D, Gallagher EJ (2021) Obesity, Type 2 Diabetes, and Cancer Risk. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2020.615375","journal-title":"Front Oncol"},{"key":"2347_CR173","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3892\/ol.2015.3887","volume":"11","author":"M Zhang","year":"2015","unstructured":"Zhang M, Chen H, Gu J (2015) Analysis of factors affecting endocrine therapy resistance in breast cancer. Oncol Lett 11:379\u2013384. https:\/\/doi.org\/10.3892\/ol.2015.3887","journal-title":"Oncol Lett"},{"key":"2347_CR174","doi-asserted-by":"publisher","DOI":"10.38212\/2224-6614.2091","author":"JHY Park","year":"2020","unstructured":"Park JHY, Kang Y-H, Sung M-K et al (2020) Diet-induced obesity, inflammation, and cancer. J Food Drug Anal. https:\/\/doi.org\/10.38212\/2224-6614.2091","journal-title":"J Food Drug Anal"},{"key":"2347_CR175","doi-asserted-by":"publisher","first-page":"4270","DOI":"10.1200\/jco.2016.67.4283","volume":"34","author":"NM Iyengar","year":"2016","unstructured":"Iyengar NM, Gucalp A, Dannenberg AJ, Hudis CA (2016) Obesity and cancer mechanisms: tumor microenvironment and inflammation. J Clin Oncol 34:4270\u20134276. https:\/\/doi.org\/10.1200\/jco.2016.67.4283","journal-title":"J Clin Oncol"},{"key":"2347_CR176","doi-asserted-by":"publisher","first-page":"101055","DOI":"10.1016\/j.plipres.2020.101055","volume":"80","author":"KC Corn","year":"2020","unstructured":"Corn KC, Windham MA, Rafat M (2020) Lipids in the tumor microenvironment: from cancer progression to treatment. Prog Lipid Res 80:101055. https:\/\/doi.org\/10.1016\/j.plipres.2020.101055","journal-title":"Prog Lipid Res"},{"key":"2347_CR177","doi-asserted-by":"publisher","DOI":"10.31083\/j.fbl2812348","author":"M He","year":"2023","unstructured":"He M, Xu S, Yan F et al (2023) Fatty acid metabolism: a new perspective in breast cancer precision therapy. Front Biosci-landmark. https:\/\/doi.org\/10.31083\/j.fbl2812348","journal-title":"Front Biosci-landmark"},{"key":"2347_CR178","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41392-024-01953-7","volume":"9","author":"Q Li","year":"2024","unstructured":"Li Q, Geng S, Luo H et al (2024) Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy. Sig Transduct Target Ther 9:266. https:\/\/doi.org\/10.1038\/s41392-024-01953-7","journal-title":"Sig Transduct Target Ther"},{"key":"2347_CR179","doi-asserted-by":"publisher","first-page":"695","DOI":"10.3892\/ol.2021.12956","volume":"22","author":"G Sun","year":"2021","unstructured":"Sun G, Yang L, Wei S et al (2021) miR-425 regulates lipophagy via SIRT1 to promote sorafenib resistance in liver cancer. Oncol Lett 22:695. https:\/\/doi.org\/10.3892\/ol.2021.12956","journal-title":"Oncol Lett"},{"key":"2347_CR180","doi-asserted-by":"publisher","DOI":"10.7150\/thno.74974cite","author":"C Wu","year":"2022","unstructured":"Wu C, Dai C, Li X et al (2022) AKR1C3-dependent lipid droplet formation confers hepatocellular carcinoma cell adaptability to targeted therapy. Theranostics. https:\/\/doi.org\/10.7150\/thno.74974cite","journal-title":"Theranostics"},{"key":"2347_CR181","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194754","author":"S-Y Yu","year":"2022","unstructured":"Yu S-Y, Luan Y, Dong R et al (2022) Adipose tissue wasting as a determinant of pancreatic cancer-related cachexia. Cancers. https:\/\/doi.org\/10.3390\/cancers14194754","journal-title":"Cancers"},{"key":"2347_CR182","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12943-025-02336-4","volume":"24","author":"S Huang","year":"2025","unstructured":"Huang S, Zhu J, Yu L et al (2025) Cancer-nervous system crosstalk: from biological mechanism to therapeutic opportunities. Mol Cancer 24:133. https:\/\/doi.org\/10.1186\/s12943-025-02336-4","journal-title":"Mol Cancer"},{"key":"2347_CR183","doi-asserted-by":"publisher","first-page":"13185","DOI":"10.3390\/ijms252313185","volume":"25","author":"A\u00c1 Moln\u00e1r","year":"2024","unstructured":"Moln\u00e1r A\u00c1, Birg\u00e9s K, Surman A, Merkely B (2024) The complex connection between myocardial dysfunction and cancer beyond cardiotoxicity: shared risk factors and common molecular pathways. Int J Mol Sci 25:13185. https:\/\/doi.org\/10.3390\/ijms252313185","journal-title":"Int J Mol Sci"},{"key":"2347_CR184","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.3390\/cancers12123741","volume":"12","author":"PJ Hunt","year":"2020","unstructured":"Hunt PJ, Kabotyanski KE, Calin GA et al (2020) Interrupting neuron\u2014tumor interactions to overcome treatment resistance. Cancers 12:3741. https:\/\/doi.org\/10.3390\/cancers12123741","journal-title":"Cancers"},{"key":"2347_CR185","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1002\/cncr.32950","volume":"126","author":"R Haldar","year":"2020","unstructured":"Haldar R, Ricon-Becker I, Radin A et al (2020) Perioperative COX2 and \u03b2\u2010adrenergic blockade improves biomarkers of tumor metastasis, immunity, and inflammation in colorectal cancer: A randomized controlled trial. Cancer 126:3991\u20134001. https:\/\/doi.org\/10.1002\/cncr.32950","journal-title":"Cancer"},{"key":"2347_CR186","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7426","author":"JW-L Eng","year":"2015","unstructured":"Eng JW-L, Reed CB, Kokolus KM et al (2015) Housing temperature-induced stress drives therapeutic resistance in murine tumour models through \u03b22-adrenergic receptor activation. Nat Commun. https:\/\/doi.org\/10.1038\/ncomms7426","journal-title":"Nat Commun"},{"key":"2347_CR187","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.molcel.2016.05.025","volume":"62","author":"M Krzywinski","year":"2016","unstructured":"Krzywinski M (2016) Visualizing Clonal Evolution in Cancer. Mol Cell 62:652\u2013656. https:\/\/doi.org\/10.1016\/j.molcel.2016.05.025","journal-title":"Mol Cell"},{"key":"2347_CR188","doi-asserted-by":"publisher","first-page":"3338","DOI":"10.1172\/jci80004","volume":"125","author":"MWL Teng","year":"2015","unstructured":"Teng MWL, Galon J, Fridman W-H, Smyth MJ (2015) From mice to humans: developments in cancer immunoediting. J Clin Investig 125:3338\u20133346. https:\/\/doi.org\/10.1172\/jci80004","journal-title":"J Clin Investig"},{"key":"2347_CR189","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/path.4884","volume":"242","author":"W Hosoda","year":"2017","unstructured":"Hosoda W, Chianchiano P, Griffin JF et al (2017) Genetic analyses of isolated high-grade pancreatic intraepithelial neoplasia (HG\u2010PanIN) reveal paucity of alterations in TP53 and SMAD4. J Pathol 242:16\u201323. https:\/\/doi.org\/10.1002\/path.4884","journal-title":"J Pathol"},{"key":"2347_CR190","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12943-015-0449-3","volume":"14","author":"M-C Yang","year":"2015","unstructured":"Yang M-C, Wang H-C, Hou Y-C et al (2015) Blockade of autophagy reduces pancreatic cancer stem cell activity and potentiates the tumoricidal effect of gemcitabine. Mol Cancer 14:179. https:\/\/doi.org\/10.1186\/s12943-015-0449-3","journal-title":"Mol Cancer"},{"key":"2347_CR191","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/nm.3854","volume":"21","author":"KS Thress","year":"2015","unstructured":"Thress KS, Paweletz CP, Felip E et al (2015) Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med 21:560\u2013562. https:\/\/doi.org\/10.1038\/nm.3854","journal-title":"Nat Med"},{"key":"2347_CR192","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002003","author":"LV Sequist","year":"2011","unstructured":"Sequist LV, Waltman BA, Dias-Santagata D et al (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.3002003","journal-title":"Sci Transl Med"},{"key":"2347_CR193","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.201800295","author":"AE Erickson","year":"2018","unstructured":"Erickson AE, Levengood SKL, Sun J et al (2018) Fabrication and characterization of chitosan\u2013hyaluronic acid scaffolds with varying stiffness for glioblastoma cell culture. Adv Healthc Mater. https:\/\/doi.org\/10.1002\/adhm.201800295","journal-title":"Adv Healthc Mater"},{"key":"2347_CR194","doi-asserted-by":"publisher","first-page":"9687","DOI":"10.7150\/thno.60851","volume":"11","author":"S Hong","year":"2021","unstructured":"Hong S, You JY, Paek K et al (2021) Inhibition of tumor progression and M2 microglial polarization by extracellular vesicle-mediated microRNA-124 in a 3D microfluidic glioblastoma microenvironment. Theranostics 11:9687\u20139704. https:\/\/doi.org\/10.7150\/thno.60851","journal-title":"Theranostics"},{"key":"2347_CR195","doi-asserted-by":"publisher","first-page":"nov122","DOI":"10.1093\/neuonc\/nov122","volume":"17","author":"WP Mason","year":"2015","unstructured":"Mason WP (2015) Blood-brain barrier-associated efflux transporters: a significant but underappreciated obstacle to drug development in glioblastoma. Neuro-oncol 17:nov122. https:\/\/doi.org\/10.1093\/neuonc\/nov122","journal-title":"Neuro-oncol"},{"key":"2347_CR196","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1158\/2159-8290.CD-20-0612","volume":"10","author":"MK Koleilat","year":"2020","unstructured":"Koleilat MK, Kwong LN (2020) Same name, different game: EGFR drives intrinsic KRASG12C inhibitor resistance in colorectal cancer. Cancer Discov 10:1094\u20131096. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0612","journal-title":"Cancer Discov"},{"key":"2347_CR197","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/cr.2009.43","volume":"19","author":"I Bisson","year":"2009","unstructured":"Bisson I, Prowse DM (2009) WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Res 19:683\u2013697. https:\/\/doi.org\/10.1038\/cr.2009.43","journal-title":"Cell Res"},{"key":"2347_CR198","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-35962-x","author":"J Chmielecki","year":"2023","unstructured":"Chmielecki J, Mok T, Wu Y-L et al (2023) Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial. Nat Commun. https:\/\/doi.org\/10.1038\/s41467-023-35962-x","journal-title":"Nat Commun"},{"key":"2347_CR199","doi-asserted-by":"publisher","first-page":"76116","DOI":"10.18632\/oncotarget.18814","volume":"8","author":"L Wang","year":"2017","unstructured":"Wang L, Cao L, Wang H et al (2017) Cancer-associated fibroblasts enhance metastatic potential of lung cancer cells through IL-6\/STAT3 signaling pathway. Oncotarget 8:76116\u201376128. https:\/\/doi.org\/10.18632\/oncotarget.18814","journal-title":"Oncotarget"},{"key":"2347_CR200","doi-asserted-by":"publisher","unstructured":"Fanning SW, Mayne CG, Dharmarajan V et al (2016) Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation. https:\/\/doi.org\/10.7554\/elife.12792","DOI":"10.7554\/elife.12792"},{"key":"2347_CR201","doi-asserted-by":"publisher","first-page":"e403","DOI":"10.1002\/mco2.403","volume":"4","author":"J-W Li","year":"2023","unstructured":"Li J-W, Deng Q-M, Zhu J-L et al (2023) Methylation of ESR1 promoter induced by SNAI2-DNMT3B complex promotes epithelial-mesenchymal transition and correlates with poor prognosis in ER\u03b1-positive breast cancers. Medcomm 4:e403. https:\/\/doi.org\/10.1002\/mco2.403","journal-title":"Medcomm"},{"key":"2347_CR202","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00985-8","author":"A Glentis","year":"2017","unstructured":"Glentis A, Oertle P, Mariani P et al (2017) Cancer-associated fibroblasts induce metalloprotease-independent cancer cell invasion of the basement membrane. Nat Commun. https:\/\/doi.org\/10.1038\/s41467-017-00985-8","journal-title":"Nat Commun"},{"key":"2347_CR203","unstructured":"Yang X, Phillips DL, Ferguson AT et al Synergistic activation of functional estrogen receptor (ER)- by DNA methyltransferase and histone deacetylase inhibition in human ER- -negative breast cancer cells"},{"key":"2347_CR204","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.canlet.2014.06.022","volume":"353","author":"F Ma","year":"2014","unstructured":"Ma F, Li H, Wang H et al (2014) Enriched CD44+\/CD24\u2009\u2013\u2009population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC). Cancer Lett 353:153\u2013159. https:\/\/doi.org\/10.1016\/j.canlet.2014.06.022","journal-title":"Cancer Lett"},{"key":"2347_CR205","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00534-2","author":"H Liu","year":"2021","unstructured":"Liu H, Liang Z, Zhou C et al (2021) Mutant KRAS triggers functional reprogramming of tumor-associated macrophages in colorectal cancer. Signal Transduct Target Ther. https:\/\/doi.org\/10.1038\/s41392-021-00534-2","journal-title":"Signal Transduct Target Ther"},{"key":"2347_CR206","doi-asserted-by":"publisher","first-page":"4914","DOI":"10.1038\/onc.2014.416","volume":"34","author":"E Lemieux","year":"2015","unstructured":"Lemieux E, Cagnol S, Beaudry K et al (2015) Oncogenic KRAS signalling promotes the wnt\/\u03b2-catenin pathway through LRP6 in colorectal cancer. Oncogene 34:4914\u20134927. https:\/\/doi.org\/10.1038\/onc.2014.416","journal-title":"Oncogene"},{"key":"2347_CR207","doi-asserted-by":"publisher","DOI":"10.7554\/elife.83140","author":"S Sayin","year":"2023","unstructured":"Sayin S, Rosener B, Li CG et al (2023) Evolved bacterial resistance to the chemotherapy gemcitabine modulates its efficacy in co-cultured cells. Elife. https:\/\/doi.org\/10.7554\/elife.83140","journal-title":"Elife"},{"key":"2347_CR208","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.3390\/cells10051170","volume":"10","author":"M Krishnamoorthy","year":"2021","unstructured":"Krishnamoorthy M, Gerhardt L, Vareki SM (2021) Immunosuppressive effects of myeloid-derived suppressor cells in cancer and immunotherapy. Cells 10:1170. https:\/\/doi.org\/10.3390\/cells10051170","journal-title":"Cells"},{"key":"2347_CR209","doi-asserted-by":"publisher","DOI":"10.1101\/2023.12.21.572810","author":"B Cong","year":"2023","unstructured":"Cong B, Stamou E, Pennel K et al (2023) WNT signalling promotes NF-\u03baB activation and drug resistance in KRAS-mutant colorectal cancer. Biorxiv. https:\/\/doi.org\/10.1101\/2023.12.21.572810","journal-title":"Biorxiv"},{"key":"2347_CR210","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-93107-w","author":"SAL van Palit","year":"2021","unstructured":"Palit SAL, van Dorp J, Vis D et al (2021) A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-021-93107-w","journal-title":"Sci Rep"},{"key":"2347_CR211","doi-asserted-by":"publisher","first-page":"100747","DOI":"10.1016\/j.tranon.2020.100747","volume":"13","author":"Y Wang","year":"2020","unstructured":"Wang Y, Singhal U, Qiao Y et al (2020) Wnt signaling drives prostate cancer bone metastatic tropism and invasion. Transl Oncol 13:100747. https:\/\/doi.org\/10.1016\/j.tranon.2020.100747","journal-title":"Transl Oncol"},{"key":"2347_CR212","doi-asserted-by":"publisher","first-page":"509","DOI":"10.31557\/apjcp.2019.20.2.509","volume":"20","author":"NH Haron","year":"2019","unstructured":"Haron NH, Hanif EAM, Manaf MRA et al (2019) Microsatellite instability and altered expressions of MLH1 and MSH2 in gastric cancer. Asian Pac J Cancer Prev 20:509\u2013517. https:\/\/doi.org\/10.31557\/apjcp.2019.20.2.509","journal-title":"Asian Pac J Cancer Prev"},{"key":"2347_CR213","doi-asserted-by":"publisher","first-page":"11325","DOI":"10.2147\/ott.s231846","volume":"12","author":"J Wang","year":"2019","unstructured":"Wang J, Lv B, Su Y et al (2019) Exosome-mediated transfer of lncRNA HOTTIP promotes cisplatin resistance in gastric cancer cells by regulating HMGA1\/miR-218 axis. OncoTargets Ther Volume 12:11325\u201311338. https:\/\/doi.org\/10.2147\/ott.s231846","journal-title":"OncoTargets Ther Volume"},{"key":"2347_CR214","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.2147\/ijn.s70228","volume":"10","author":"W-J Zeng","year":"2015","unstructured":"Zeng W-J, Peng C-W, Yuan J-P et al (2015) Quantum dot-based multiplexed imaging in malignant ascites: a new model for malignant ascites classification. Int J Nanomed 10:1759. https:\/\/doi.org\/10.2147\/ijn.s70228","journal-title":"Int J Nanomed"},{"key":"2347_CR215","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.3389\/fonc.2019.01267","volume":"9","author":"O Kersy","year":"2019","unstructured":"Kersy O, Loewenstein S, Lubezky N et al (2019) Omental tissue-mediated tumorigenesis of gastric cancer peritoneal metastases. Front Oncol 9:1267. https:\/\/doi.org\/10.3389\/fonc.2019.01267","journal-title":"Front Oncol"},{"key":"2347_CR216","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41852-z","author":"Z Ding","year":"2023","unstructured":"Ding Z, Pan Y, Shang T et al (2023) URI alleviates tyrosine kinase inhibitors-induced ferroptosis by reprogramming lipid metabolism in p53 wild-type liver cancers. Nat Commun. https:\/\/doi.org\/10.1038\/s41467-023-41852-z","journal-title":"Nat Commun"},{"key":"2347_CR217","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.cell.2019.08.052","volume":"179","author":"Q Gao","year":"2019","unstructured":"Gao Q, Zhu H, Dong L et al (2019) Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma. Cell 179:561\u2013577e22. https:\/\/doi.org\/10.1016\/j.cell.2019.08.052","journal-title":"Cell"},{"key":"2347_CR218","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1382256","author":"Z Li","year":"2024","unstructured":"Li Z, Duan D, Li L et al (2024) Frontiers | tumor-associated macrophages in anti-PD-1\/PD-L1 immunotherapy for hepatocellular carcinoma: recent research progress. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2024.1382256","journal-title":"Front Pharmacol"},{"key":"2347_CR219","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1038\/oncsis.2017.22","volume":"6","author":"R Chauhan","year":"2017","unstructured":"Chauhan R, Churchill ND, Mulrooney-Cousins PM, Michalak TI (2017) Initial sites of hepadnavirus integration into host genome in human hepatocytes and in the woodchuck model of hepatitis B-associated hepatocellular carcinoma. Oncogenesis 6:e317\u2013e317. https:\/\/doi.org\/10.1038\/oncsis.2017.22","journal-title":"Oncogenesis"},{"key":"2347_CR220","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/s41419-023-06344-4","volume":"14","author":"H Xu","year":"2023","unstructured":"Xu H, Tan M, Hou G-Q et al (2023) Blockade of DDR1\/PYK2\/ERK signaling suggesting SH2 superbinder as a novel autophagy inhibitor for pancreatic cancer. Cell Death Dis 14:811. https:\/\/doi.org\/10.1038\/s41419-023-06344-4","journal-title":"Cell Death Dis"},{"key":"2347_CR221","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-024-07268-1","author":"M Kalli","year":"2024","unstructured":"Kalli M, Mpekris F, Charalambous A et al (2024) Mechanical forces inducing oxaliplatin resistance in pancreatic cancer can be targeted by autophagy inhibition. Commun Biol. https:\/\/doi.org\/10.1038\/s42003-024-07268-1","journal-title":"Commun Biol"},{"key":"2347_CR222","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1460616","author":"Z Zhou","year":"2024","unstructured":"Zhou Z, Zhang P, Li J et al (2024) Autophagy and the pancreas: Healthy and disease states. Front Cell Dev Biol. https:\/\/doi.org\/10.3389\/fcell.2024.1460616","journal-title":"Front Cell Dev Biol"},{"key":"2347_CR223","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ejca.2017.04.016","volume":"79","author":"I Ruscito","year":"2017","unstructured":"Ruscito I, Castillo-Tong DC, Vergote I et al (2017) Exploring the clonal evolution of CD133\/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the ovarian cancer therapy-innovative models prolong survival (OCTIPS) consortium. Eur J Cancer 79:214\u2013225. https:\/\/doi.org\/10.1016\/j.ejca.2017.04.016","journal-title":"Eur J Cancer"},{"key":"2347_CR224","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1038\/s41388-018-0637-x","volume":"38","author":"T Motohara","year":"2018","unstructured":"Motohara T, Masuda K, Morotti M et al (2018) An evolving story of the metastatic voyage of ovarian cancer cells: cellular and molecular orchestration of the adipose-rich metastatic microenvironment. Oncogene 38:2885\u20132898. https:\/\/doi.org\/10.1038\/s41388-018-0637-x","journal-title":"Oncogene"},{"key":"2347_CR225","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1002\/ijc.32854","volume":"146","author":"M Yoshihara","year":"2020","unstructured":"Yoshihara M, Kajiyama H, Yokoi A et al (2020) Ovarian cancer-associated mesothelial cells induce acquired platinum\u2010resistance in peritoneal metastasis via the FN1\/akt signaling pathway. Int J Cancer 146:2268\u20132280. https:\/\/doi.org\/10.1002\/ijc.32854","journal-title":"Int J Cancer"},{"key":"2347_CR226","doi-asserted-by":"publisher","first-page":"101917","DOI":"10.1016\/j.tranon.2024.101917","volume":"44","author":"B Yang","year":"2024","unstructured":"Yang B, Dai M (2024) High-dimensional deconstruction of ovarian cancer at single-cell precision reveals HEBP2 that reshape the TIME and drive carboplatin resistance. Transl Oncol 44:101917. https:\/\/doi.org\/10.1016\/j.tranon.2024.101917","journal-title":"Transl Oncol"},{"key":"2347_CR227","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-022-00569-9","author":"X Liang","year":"2022","unstructured":"Liang X, Wang Z, Dai Z et al (2022) Glioblastoma glycolytic signature predicts unfavorable prognosis, immunological heterogeneity, and ENO1 promotes microglia M2 polarization and cancer cell malignancy. Cancer Gene Ther. https:\/\/doi.org\/10.1038\/s41417-022-00569-9","journal-title":"Cancer Gene Ther"},{"key":"2347_CR228","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.927570","author":"M Suleman","year":"2022","unstructured":"Suleman M, Umme-I-Hani S, Salman M et al (2022) Sequence-structure functional implications and molecular simulation of high deleterious nonsynonymous substitutions in IDH1 revealed the mechanism of drug resistance in glioma. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2022.927570","journal-title":"Front Pharmacol"},{"key":"2347_CR229","doi-asserted-by":"publisher","first-page":"805628","DOI":"10.3389\/fonc.2021.805628","volume":"11","author":"AG Bhargav","year":"2022","unstructured":"Bhargav AG, Domino JS, Chamoun R, Thomas SM (2022) Mechanical properties in the glioma microenvironment: emerging insights and theranostic opportunities. Front Oncol 11:805628. https:\/\/doi.org\/10.3389\/fonc.2021.805628","journal-title":"Front Oncol"},{"key":"2347_CR230","doi-asserted-by":"publisher","first-page":"6795","DOI":"10.12659\/msm.909205","volume":"24","author":"D Zhou","year":"2018","unstructured":"Zhou D, Li Z, Bai X (2018) BRAF V600E and RET\/PTC promote the activity of nuclear factor-\u03baB, inflammatory mediators, and lymph node metastasis in papillary thyroid carcinoma: a study of 50 patients in inner mongolia. Med Sci Monit 24:6795\u20136808. https:\/\/doi.org\/10.12659\/msm.909205","journal-title":"Med Sci Monit"},{"key":"2347_CR231","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00563-4","author":"V Subbiah","year":"2024","unstructured":"Subbiah V, Gouda MA, Iorgulescu JB et al (2024) Adaptive darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer. npj Precis Oncol. https:\/\/doi.org\/10.1038\/s41698-024-00563-4","journal-title":"npj Precis Oncol"},{"key":"2347_CR232","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/S0092-8674(00)81731-6","volume":"94","author":"D Fukumura","year":"1998","unstructured":"Fukumura D, Xavier R, Sugiura T et al (1998) Tumor induction of VEGF promoter activity in stromal cells. Cell 94:715\u2013725. https:\/\/doi.org\/10.1016\/S0092-8674(00)81731-6","journal-title":"Cell"},{"key":"2347_CR233","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1158\/1541-7786.mcr-14-0689","volume":"13","author":"B Decker","year":"2015","unstructured":"Decker B, Parker HG, Dhawan D et al (2015) Homologous mutation to human BRAF V600E is common in naturally occurring canine bladder cancer\u2013evidence for a relevant model system and urine-based diagnostic test. Mol Cancer Res 13:993\u20131002. https:\/\/doi.org\/10.1158\/1541-7786.mcr-14-0689","journal-title":"Mol Cancer Res"},{"key":"2347_CR234","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1158\/2159-8290.cd-17-1260","volume":"8","author":"SB Maron","year":"2018","unstructured":"Maron SB, Alpert L, Kwak HA et al (2018) Targeted therapies for targeted populations: anti-EGFR treatment for EGFR-amplified gastroesophageal adenocarcinoma. Cancer Discov 8:696\u2013713. https:\/\/doi.org\/10.1158\/2159-8290.cd-17-1260","journal-title":"Cancer Discov"},{"key":"2347_CR235","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3892\/or.2016.4822","volume":"36","author":"Y Cui","year":"2016","unstructured":"Cui Y, Li Y-Y, Li J et al (2016) STAT3 regulates hypoxia-induced epithelial mesenchymal transition in oesophageal squamous cell cancer. Oncol Rep 36:108\u2013116. https:\/\/doi.org\/10.3892\/or.2016.4822","journal-title":"Oncol Rep"},{"key":"2347_CR236","doi-asserted-by":"publisher","first-page":"e90836","DOI":"10.1371\/journal.pone.0090836","volume":"9","author":"Y Zhao","year":"2014","unstructured":"Zhao Y, Zhou W, Xue L et al (2014) Nicotine activates YAP1 through nAChRs mediated signaling in esophageal squamous cell cancer (ESCC). PLoS ONE 9:e90836. https:\/\/doi.org\/10.1371\/journal.pone.0090836","journal-title":"PLoS ONE"},{"key":"2347_CR237","doi-asserted-by":"publisher","DOI":"10.7554\/elife.84051","author":"S Yuan","year":"2023","unstructured":"Yuan S, Chen J, Ruan X et al (2023) Smoking, alcohol consumption, and 24 gastrointestinal diseases: mendelian randomization analysis. Elife. https:\/\/doi.org\/10.7554\/elife.84051","journal-title":"Elife"},{"key":"2347_CR238","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/ajg.2014.71","volume":"109","author":"A Prabhu","year":"2014","unstructured":"Prabhu A, Obi KO, Rubenstein JH (2014) The synergistic effects of alcohol and tobacco consumption on the risk of esophageal squamous cell carcinoma: a meta-analysis. Am J Gastroenterol 109:822\u2013827. https:\/\/doi.org\/10.1038\/ajg.2014.71","journal-title":"Am J Gastroenterol"},{"key":"2347_CR239","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ccell.2020.05.010","volume":"38","author":"LF Escobar-Hoyos","year":"2020","unstructured":"Escobar-Hoyos LF, Penson A, Kannan R et al (2020) Altered RNA splicing by mutant p53 activates oncogenic RAS signaling in pancreatic cancer. Cancer Cell 38:198\u2013211e8. https:\/\/doi.org\/10.1016\/j.ccell.2020.05.010","journal-title":"Cancer Cell"},{"key":"2347_CR240","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/bjc.2011.222","volume":"105","author":"K Iida","year":"2011","unstructured":"Iida K, Nakayama K, Rahman MT et al (2011) EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target. Br J Cancer 105:420\u2013427. https:\/\/doi.org\/10.1038\/bjc.2011.222","journal-title":"Br J Cancer"},{"key":"2347_CR241","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-98527-2","author":"I Kuno","year":"2021","unstructured":"Kuno I, Takayanagi D, Asami Y et al (2021) TP53 mutants and non-HPV16\/18 genotypes are poor prognostic factors for concurrent chemoradiotherapy in locally advanced cervical cancer. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-021-98527-2","journal-title":"Sci Rep"},{"key":"2347_CR242","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/5829676","volume":"2019","author":"S-S Seo","year":"2019","unstructured":"Seo S-S, Oh HY, Kim MK et al (2019) Combined effect of secondhand smoking and alcohol drinking on risk of persistent human papillomavirus infection. Biomed Res Int 2019:1\u20139. https:\/\/doi.org\/10.1155\/2019\/5829676","journal-title":"Biomed Res Int"},{"key":"2347_CR243","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2016.02.021","author":"A Hildesheim","year":"2016","unstructured":"Hildesheim A, Gonzalez P, Kreimer AR et al (2016) Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment. Am J Obstet Gynecol. https:\/\/doi.org\/10.1016\/j.ajog.2016.02.021","journal-title":"Am J Obstet Gynecol"},{"key":"2347_CR244","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.3390\/ijms23073818","volume":"23","author":"S Nair","year":"2022","unstructured":"Nair S, Bonner JA, Bredel M (2022) EGFR mutations in head and neck squamous cell carcinoma. Int J Mol Sci 23:3818. https:\/\/doi.org\/10.3390\/ijms23073818","journal-title":"Int J Mol Sci"},{"key":"2347_CR245","doi-asserted-by":"publisher","DOI":"10.3892\/or.2022.8269","author":"E Wiechec","year":"2022","unstructured":"Wiechec E, Matic N, Ali A, Roberg K (2022) Hypoxia induces radioresistance, epithelial\u2013mesenchymal transition, cancer stem cell\u2013like phenotype and changes in genes possessing multiple biological functions in head and neck squamous cell carcinoma. Oncol Rep. https:\/\/doi.org\/10.3892\/or.2022.8269","journal-title":"Oncol Rep"},{"key":"2347_CR246","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1182\/blood-2016-07-418434","volume":"128","author":"B Falini","year":"2016","unstructured":"Falini B, Martelli MP, Tiacci E (2016) BRAF V600E mutation in hairy cell leukemia: from bench to bedside. Blood 128:1918\u20131927. https:\/\/doi.org\/10.1182\/blood-2016-07-418434","journal-title":"Blood"},{"key":"2347_CR247","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1122699","author":"E Gargiulo","year":"2023","unstructured":"Gargiulo E, Giordano M, Niemann CU et al (2023) The protective role of the microenvironment in hairy cell leukemia treatment: facts and perspectives. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2023.1122699","journal-title":"Front Oncol"},{"key":"2347_CR248","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJM200107263450402","volume":"345","author":"RJ Kreitman","year":"2001","unstructured":"Kreitman RJ, Wilson WH, Bergeron K et al (2001) Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 345:241\u2013247. https:\/\/doi.org\/10.1056\/NEJM200107263450402","journal-title":"N Engl J Med"},{"key":"2347_CR249","doi-asserted-by":"publisher","first-page":"3645","DOI":"10.1111\/cas.15073","volume":"112","author":"A Kitadate","year":"2021","unstructured":"Kitadate A, Terao T, Narita K et al (2021) Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence. Cancer Sci 112:3645\u20133654. https:\/\/doi.org\/10.1111\/cas.15073","journal-title":"Cancer Sci"},{"key":"2347_CR250","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1158\/2326-6066.cir-15-0296","volume":"4","author":"M Ishibashi","year":"2016","unstructured":"Ishibashi M, Tamura H, Sunakawa M et al (2016) Myeloma drug resistance induced by binding of myeloma B7-H1 (PD-L1) to PD-1. Cancer Immunol Res 4:779\u2013788. https:\/\/doi.org\/10.1158\/2326-6066.cir-15-0296","journal-title":"Cancer Immunol Res"},{"key":"2347_CR251","doi-asserted-by":"publisher","first-page":"101177","DOI":"10.1016\/j.neo.2025.101177","volume":"66","author":"S Crist\u00f3bal-Vargas","year":"2025","unstructured":"Crist\u00f3bal-Vargas S, Cuadrado M, Guti\u00e9rrez NC (2025) MYC alterations in multiple myeloma: genetic insights and prognostic impact. Neoplasia 66:101177. https:\/\/doi.org\/10.1016\/j.neo.2025.101177","journal-title":"Neoplasia"},{"key":"2347_CR252","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.3390\/cancers16122249","volume":"16","author":"H Slika","year":"2024","unstructured":"Slika H, Shahani A, Wahi R et al (2024) Overcoming treatment resistance in medulloblastoma: underlying mechanisms and potential strategies. Cancers 16:2249. https:\/\/doi.org\/10.3390\/cancers16122249","journal-title":"Cancers"},{"key":"2347_CR253","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.1200\/jco.2010.33.8590","volume":"29","author":"JC Lindsey","year":"2011","unstructured":"Lindsey JC, Hill RM, Megahed H et al (2011) TP53 mutations in favorable-risk wnt\/wingless-subtype medulloblastomas. J Clin Oncol 29:e344\u2013e346. https:\/\/doi.org\/10.1200\/jco.2010.33.8590","journal-title":"J Clin Oncol"},{"key":"2347_CR254","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/nature13109","volume":"506","author":"M Parker","year":"2014","unstructured":"Parker M, Mohankumar KM, Punchihewa C et al (2014) C11orf95\u2013RELA fusions drive oncogenic NF-\u03baB signalling in ependymoma. Nature 506:451\u2013455. https:\/\/doi.org\/10.1038\/nature13109","journal-title":"Nature"},{"key":"2347_CR255","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-021-01135-4","author":"T Ozawa","year":"2021","unstructured":"Ozawa T, Kaneko S, Szulzewsky F et al (2021) C11orf95-RELA fusion drives aberrant gene expression through the unique epigenetic regulation for ependymoma formation. Acta Neuropathol Commun. https:\/\/doi.org\/10.1186\/s40478-021-01135-4","journal-title":"Acta Neuropathol Commun"},{"key":"2347_CR256","doi-asserted-by":"publisher","first-page":"4877","DOI":"10.2147\/ott.s249586","volume":"13","author":"H Zhou","year":"2020","unstructured":"Zhou H, Hu P, Yan X et al (2020) Ibrutinib in chronic lymphocytic leukemia: clinical applications, drug resistance, and prospects. OncoTargets Ther Volume 13:4877\u20134892. https:\/\/doi.org\/10.2147\/ott.s249586","journal-title":"OncoTargets Ther Volume"},{"key":"2347_CR257","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1182\/bloodadvances.2021006941","volume":"7","author":"C Sun","year":"2023","unstructured":"Sun C, Chen Y-C, Martinez Zurita A et al (2023) The immune microenvironment shapes transcriptional and genetic heterogeneity in chronic lymphocytic leukemia. Blood Adv 7:145\u2013158. https:\/\/doi.org\/10.1182\/bloodadvances.2021006941","journal-title":"Blood Adv"},{"key":"2347_CR258","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1053\/j.seminhematol.2024.04.002","volume":"61","author":"JT Patton","year":"2024","unstructured":"Patton JT, Woyach JA (2024) Targeting the B cell receptor signaling pathway in chronic lymphocytic leukemia. Semin Hematol 61:100\u2013108. https:\/\/doi.org\/10.1053\/j.seminhematol.2024.04.002","journal-title":"Semin Hematol"},{"key":"2347_CR259","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/s41375-018-0250-6","volume":"33","author":"BS Hanna","year":"2019","unstructured":"Hanna BS, Roessner PM, Yazdanparast H et al (2019) Control of chronic lymphocytic leukemia development by clonally-expanded CD8\u2009+\u2009T-cells that undergo functional exhaustion in secondary lymphoid tissues. Leukemia 33:625\u2013637. https:\/\/doi.org\/10.1038\/s41375-018-0250-6","journal-title":"Leukemia"},{"key":"2347_CR260","doi-asserted-by":"publisher","first-page":"10214","DOI":"10.3390\/ijms251810214","volume":"25","author":"F Fei","year":"2024","unstructured":"Fei F, Jariwala A, Pullarkat S et al (2024) Genomic landscape of myelodysplastic\/myeloproliferative neoplasms: a multi-central study. Int J Mol Sci 25:10214. https:\/\/doi.org\/10.3390\/ijms251810214","journal-title":"Int J Mol Sci"},{"key":"2347_CR261","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1159\/000535628","volume":"147","author":"J DiGennaro","year":"2023","unstructured":"DiGennaro J, Sallman DA (2023) TP53-mutated myelodysplastic syndrome and acute myeloid leukemia: current guidelines, therapies, and future considerations. Acta Haematol 147:175\u2013185. https:\/\/doi.org\/10.1159\/000535628","journal-title":"Acta Haematol"},{"key":"2347_CR262","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00277-010-1091-1","volume":"90","author":"N Gattermann","year":"2010","unstructured":"Gattermann N, Rachmilewitz EA (2010) Iron overload in MDS-pathophysiology, diagnosis, and complications. Ann Hematol 90:1\u201310. https:\/\/doi.org\/10.1007\/s00277-010-1091-1","journal-title":"Ann Hematol"},{"key":"2347_CR263","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1080\/16078454.2020.1870373","volume":"26","author":"LSA Chan","year":"2021","unstructured":"Chan LSA, Gu LC, Leitch HA, Wells RA (2021) Intracellular ROS profile in hematopoietic progenitors of MDS patients: association with blast count and iron overload. Hematology 26:88\u201395. https:\/\/doi.org\/10.1080\/16078454.2020.1870373","journal-title":"Hematology"},{"key":"2347_CR264","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1200\/jco.2016.66.4482","volume":"34","author":"MGM Roemer","year":"2016","unstructured":"Roemer MGM, Advani RH, Ligon AH et al (2016) PD-L1 and PD-L2 genetic alterations define classical hodgkin lymphoma and predict outcome. J Clin Oncol 34:2690\u20132697. https:\/\/doi.org\/10.1200\/jco.2016.66.4482","journal-title":"J Clin Oncol"},{"key":"2347_CR265","doi-asserted-by":"publisher","first-page":"3881","DOI":"10.1158\/1078-0432.ccr-24-0942","volume":"30","author":"M Pourmaleki","year":"2024","unstructured":"Pourmaleki M, Jones CJ, Mellinghoff SD et al (2024) Multiplexed spatial profiling of hodgkin reed-sternberg cell neighborhoods in classic hodgkin lymphoma. Clin Cancer Res 30:3881\u20133893. https:\/\/doi.org\/10.1158\/1078-0432.ccr-24-0942","journal-title":"Clin Cancer Res"},{"key":"2347_CR266","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.3390\/cancers17091433","volume":"17","author":"MN Alibrahim","year":"2025","unstructured":"Alibrahim MN, Gloghini A, Carbone A (2025) Immune deficiency\/dysregulation-associated EBV-positive classic hodgkin lymphoma. Cancers 17:1433. https:\/\/doi.org\/10.3390\/cancers17091433","journal-title":"Cancers"},{"key":"2347_CR267","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1476-4598-9-32","volume":"9","author":"T-Y Liu","year":"2010","unstructured":"Liu T-Y, Wu S-J, Huang M-H et al (2010) EBV-positive hodgkin lymphoma is associated with suppression of p21cip1\/waf1 and a worse prognosis. Mol Cancer 9:32. https:\/\/doi.org\/10.1186\/1476-4598-9-32","journal-title":"Mol Cancer"},{"key":"2347_CR268","doi-asserted-by":"publisher","first-page":"88","DOI":"10.30476\/ijms.2023.97287.2896","volume":"49","author":"MA Alabiad","year":"2024","unstructured":"Alabiad MA, Said WMM, Saad RHF et al (2024) Epstein-barr virus promotes tumorigenicity and worsens hodgkin lymphoma prognosis by activating JAK\/STAT and NF-\u03baB signaling pathways. Iran J Med Sci 49:88\u2013100. https:\/\/doi.org\/10.30476\/ijms.2023.97287.2896","journal-title":"Iran J Med Sci"},{"key":"2347_CR269","doi-asserted-by":"publisher","first-page":"e70317","DOI":"10.1002\/cam4.70317","volume":"13","author":"Z Li","year":"2024","unstructured":"Li Z, Peng D, Deng J et al (2024) New ABL1 kinase domain mutations in BCR::ABL1-positive acute lymphoblastic leukemia. Cancer Med 13:e70317. https:\/\/doi.org\/10.1002\/cam4.70317","journal-title":"Cancer Med"},{"key":"2347_CR270","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3904\/kjim.2016.244","volume":"32","author":"B-S Cho","year":"2017","unstructured":"Cho B-S, Kim H-J, Konopleva M (2017) Targeting the CXCL12\/CXCR4 axis in acute myeloid leukemia: from bench to bedside. Korean J Intern Med 32:248\u2013257. https:\/\/doi.org\/10.3904\/kjim.2016.244","journal-title":"Korean J Intern Med"},{"key":"2347_CR271","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-10724-6","author":"W Li","year":"2023","unstructured":"Li W, Liu S, Wang C et al (2023) DNMT3A low-expression is correlated to poor prognosis in childhood B-ALL and confers resistance to daunorubicin on leukemic cells. BMC Cancer. https:\/\/doi.org\/10.1186\/s12885-023-10724-6","journal-title":"BMC Cancer"},{"key":"2347_CR272","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/2050-7771-1-13","volume":"1","author":"S L\u00fc","year":"2013","unstructured":"L\u00fc S, Wang J (2013) The resistance mechanisms of proteasome inhibitor bortezomib. Biomark Res 1:13. https:\/\/doi.org\/10.1186\/2050-7771-1-13","journal-title":"Biomark Res"},{"key":"2347_CR273","doi-asserted-by":"publisher","first-page":"613","DOI":"10.3390\/ijms21020613","volume":"21","author":"R Ria","year":"2020","unstructured":"Ria R, Vacca A (2020) Bone marrow stromal cells-induced drug resistance in multiple myeloma. Int J Mol Sci 21:613. https:\/\/doi.org\/10.3390\/ijms21020613","journal-title":"Int J Mol Sci"},{"key":"2347_CR274","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-022-00380-z","author":"C Giallongo","year":"2022","unstructured":"Giallongo C, Dulcamare I, Tibullo D et al (2022) CXCL12\/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment. Oncogenesis. https:\/\/doi.org\/10.1038\/s41389-022-00380-z","journal-title":"Oncogenesis"},{"key":"2347_CR275","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.exphem.2009.04.001","volume":"37","author":"S L\u00fc","year":"2009","unstructured":"L\u00fc S, Yang J, Chen Z et al (2009) Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma\/leukemia cells derived from the jurkat cell line. Exp Hematol 37:831\u2013837. https:\/\/doi.org\/10.1016\/j.exphem.2009.04.001","journal-title":"Exp Hematol"},{"key":"2347_CR276","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s41065-025-00563-9","volume":"162","author":"Z Lu","year":"2025","unstructured":"Lu Z, Kong F, Sun J et al (2025) Integrated single-cell and bulk transcriptome analysis revealed high plasticity subpopulation and promising diagnosis model for clear cell renal cell carcinoma. Hereditas 162:198. https:\/\/doi.org\/10.1186\/s41065-025-00563-9","journal-title":"Hereditas"},{"key":"2347_CR277","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s13046-021-01961-3","volume":"40","author":"R Sharma","year":"2021","unstructured":"Sharma R, Kadife E, Myers M et al (2021) Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma. J Exp Clin Cancer Res 40:186. https:\/\/doi.org\/10.1186\/s13046-021-01961-3","journal-title":"J Exp Clin Cancer Res"},{"key":"2347_CR278","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.621278","author":"A Marquardt","year":"2021","unstructured":"Marquardt A, Solimando AG, Kerscher A et al (2021) Subgroup-Independent Mapping of Renal Cell Carcinoma\u2014Machine Learning Reveals Prognostic Mitochondrial Gene Signature Beyond Histopathologic Boundaries. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2021.621278","journal-title":"Front Oncol"},{"key":"2347_CR279","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6712","author":"J M\u00fcller","year":"2014","unstructured":"M\u00fcller J, Krijgsman O, Tsoi J et al (2014) Low MITF\/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nat Commun. https:\/\/doi.org\/10.1038\/ncomms6712","journal-title":"Nat Commun"},{"key":"2347_CR280","doi-asserted-by":"publisher","first-page":"462","DOI":"10.15252\/embj.201592081","volume":"35","author":"MH Kim","year":"2015","unstructured":"Kim MH, Kim J, Hong H et al (2015) Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP\/TAZ activation. EMBO J 35:462\u2013478. https:\/\/doi.org\/10.15252\/embj.201592081","journal-title":"EMBO J"},{"key":"2347_CR281","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.3390\/ijms19123844","volume":"19","author":"M Czyz","year":"2018","unstructured":"Czyz M (2018) HGF\/c-MET Signaling in Melanocytes and Melanoma. Int J Mol Sci 19:3844. https:\/\/doi.org\/10.3390\/ijms19123844","journal-title":"Int J Mol Sci"},{"key":"2347_CR282","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.3390\/cancers13061253","volume":"13","author":"H-T Tzeng","year":"2021","unstructured":"Tzeng H-T, Yang J-L, Tseng Y-J et al (2021) Plasminogen Activator Inhibitor-1 Secretion by Autophagy Contributes to Melanoma Resistance to Chemotherapy through Tumor Microenvironment Modulation. Cancers 13:1253. https:\/\/doi.org\/10.3390\/cancers13061253","journal-title":"Cancers"},{"key":"2347_CR283","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1158\/2159-8290.CD-15-1483","volume":"6","author":"C Alix-Panabi\u00e8res","year":"2016","unstructured":"Alix-Panabi\u00e8res C, Pantel K (2016) Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. Cancer Discov 6:479\u2013491. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-1483","journal-title":"Cancer Discov"},{"key":"2347_CR284","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s41571-020-0392-0","volume":"17","author":"A Dasari","year":"2020","unstructured":"Dasari A, Morris VK, Allegra CJ et al (2020) ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal\u2013Anal Task Forces whitepaper. Nat Rev Clin Oncol 17:757\u2013770. https:\/\/doi.org\/10.1038\/s41571-020-0392-0","journal-title":"Nat Rev Clin Oncol"},{"key":"2347_CR285","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/S0090-8258(21)00699-5","volume":"162","author":"M Cowan","year":"2021","unstructured":"Cowan M, Xie P, Chen S et al (2021) Immune markers of response to pembrolizumab and guadecitabine in platinum resistant ovarian cancer utilizing multiplex immunohistochemistry (mIHC). Gynecol Oncol 162:S28\u2013S29. https:\/\/doi.org\/10.1016\/S0090-8258(21)00699-5","journal-title":"Gynecol Oncol"},{"key":"2347_CR286","doi-asserted-by":"publisher","first-page":"e70523","DOI":"10.1002\/cam4.70523","volume":"14","author":"AK Sun","year":"2025","unstructured":"Sun AK, Fan S, Choi SW (2025) Exploring Multiplex Immunohistochemistry (mIHC) Techniques and Histopathology Image Analysis: Current Practice and Potential for Clinical Incorporation. Cancer Med 14:e70523. https:\/\/doi.org\/10.1002\/cam4.70523","journal-title":"Cancer Med"},{"key":"2347_CR287","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/jpm16010008","volume":"16","author":"U Ozkerim","year":"2025","unstructured":"Ozkerim U, Isik D, Kinikoglu O et al (2025) Development of a Machine Learning-Based Prognostic Model Using Systemic Inflammation Markers in Patients Receiving Nivolumab Immunotherapy: A Real-World Cohort Study. JPM 16:8. https:\/\/doi.org\/10.3390\/jpm16010008","journal-title":"JPM"},{"key":"2347_CR288","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00629","author":"EM De Matos-Neto","year":"2015","unstructured":"De Matos-Neto EM, Lima JDCC, De Pereira WO et al (2015) Systemic Inflammation in Cachexia \u2013 Is Tumor Cytokine Expression Profile the Culprit? Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2015.00629","journal-title":"Front Immunol"},{"key":"2347_CR289","doi-asserted-by":"publisher","unstructured":"The TRACERx consortium, The PEACE consortium, Abbosh C et al (2017) Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature 545:446\u2013451. https:\/\/doi.org\/10.1038\/nature22364","DOI":"10.1038\/nature22364"},{"key":"2347_CR290","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.jtho.2023.03.012","volume":"18","author":"D Sun","year":"2023","unstructured":"Sun D, Liu J, Zhou H et al (2023) Classification of Tumor Immune Microenvironment According to Programmed Death-Ligand 1 Expression and Immune Infiltration Predicts Response to Immunotherapy Plus Chemotherapy in Advanced Patients With NSCLC. J Thorac Oncol 18:869\u2013881. https:\/\/doi.org\/10.1016\/j.jtho.2023.03.012","journal-title":"J Thorac Oncol"},{"key":"2347_CR291","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1158\/2767-9764.CRC-22-0258","volume":"2","author":"MS Frank","year":"2022","unstructured":"Frank MS, Andersen CSA, Ahlborn LB et al (2022) Circulating Tumor DNA Monitoring Reveals Molecular Progression before Radiologic Progression in a Real-life Cohort of Patients with Advanced Non\u2013small Cell Lung Cancer. Cancer Res Commun 2:1174\u20131187. https:\/\/doi.org\/10.1158\/2767-9764.CRC-22-0258","journal-title":"Cancer Res Commun"},{"key":"2347_CR292","doi-asserted-by":"publisher","first-page":"e16958","DOI":"10.7717\/peerj.16958","volume":"12","author":"M Cui","year":"2024","unstructured":"Cui M, Dong H, Duan W et al (2024) The relationship between cancer associated fibroblasts biomarkers and prognosis of breast cancer: a systematic review and meta-analysis. PeerJ 12:e16958. https:\/\/doi.org\/10.7717\/peerj.16958","journal-title":"PeerJ"},{"key":"2347_CR293","doi-asserted-by":"publisher","first-page":"588","DOI":"10.3390\/cancers11050588","volume":"11","author":"MG Van Mackelenbergh","year":"2019","unstructured":"Van Mackelenbergh MG, Stroes CI, Spijker R et al (2019) Clinical Trials Targeting the Stroma in Pancreatic Cancer: A Systematic Review and Meta-Analysis. Cancers 11:588. https:\/\/doi.org\/10.3390\/cancers11050588","journal-title":"Cancers"},{"key":"2347_CR294","doi-asserted-by":"publisher","first-page":"e241270","DOI":"10.1001\/jamahealthforum.2024.1270","volume":"5","author":"Y Li","year":"2024","unstructured":"Li Y, Heer AK, Sloane HS et al (2024) Budget Impact Analysis of Circulating Tumor DNA Testing for Colon Cancer in Commercial Health and Medicare Advantage Plans. JAMA Health Forum 5:e241270. https:\/\/doi.org\/10.1001\/jamahealthforum.2024.1270","journal-title":"JAMA Health Forum"},{"key":"2347_CR295","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/cac2.12023","volume":"40","author":"WCC Tan","year":"2020","unstructured":"Tan WCC, Nerurkar SN, Cai HY et al (2020) Overview of multiplex immunohistochemistry\/immunofluorescence techniques in the era of cancer immunotherapy. Cancer Commun 40:135\u2013153. https:\/\/doi.org\/10.1002\/cac2.12023","journal-title":"Cancer Commun"},{"key":"2347_CR296","doi-asserted-by":"publisher","first-page":"6945","DOI":"10.3390\/s21216945","volume":"21","author":"S-H Yun","year":"2021","unstructured":"Yun S-H, Park J-S, Koo S-B-N et al (2021) ost-Effective Multiplex Fluorescence Detection System for PCR Chip. Sensors 21:6945. https:\/\/doi.org\/10.3390\/s21216945","journal-title":"Sensors"},{"key":"2347_CR297","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1093\/jjco\/hyad034","volume":"53","author":"H Uemura","year":"2023","unstructured":"Uemura H, Shinohara N, Tomita Y et al (2023) The safety profile of nivolumab plus ipilimumab combination therapy in Japanese patients with renal cell carcinoma: results from post-marketing surveillance. Jpn J Clin Oncol 53:730\u2013737. https:\/\/doi.org\/10.1093\/jjco\/hyad034","journal-title":"Jpn J Clin Oncol"},{"key":"2347_CR298","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/nm.3564","volume":"20","author":"PT Spellman","year":"2014","unstructured":"Spellman PT, Gray JW (2014) Detecting cancer by monitoring circulating tumor DNA. Nat Med 20:474\u2013475. https:\/\/doi.org\/10.1038\/nm.3564","journal-title":"Nat Med"},{"key":"2347_CR299","doi-asserted-by":"publisher","first-page":"395","DOI":"10.5301\/jbm.5000222","volume":"31","author":"Z-L Liu","year":"2016","unstructured":"Liu Z-L, Zeng T-T, Zhou X-J et al (2016) Neutrophil-Lymphocyte Ratio as a Prognostic Marker for Chemotherapy in Advanced Lung Cancer. Int J Biol Markers 31:395\u2013401. https:\/\/doi.org\/10.5301\/jbm.5000222","journal-title":"Int J Biol Markers"},{"key":"2347_CR300","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12911-018-0680-0","volume":"18","author":"F Singer","year":"2018","unstructured":"Singer F, Irmisch A, Toussaint NC et al (2018) SwissMTB: establishing comprehensive molecular cancer diagnostics in Swiss clinics. BMC Med Inf Decis Mak 18:89. https:\/\/doi.org\/10.1186\/s12911-018-0680-0","journal-title":"BMC Med Inf Decis Mak"},{"key":"2347_CR301","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41698-025-01229-5","volume":"10","author":"T Mehra","year":"2025","unstructured":"Mehra T, Menges D, Gosztonyi B et al (2025) Comparative cost analysis of a diagnostic multi-omics platform for decision support in advanced cancer \u2013 results from the Tumor Profiler Melanoma project. npj Precis Onc 10:35. https:\/\/doi.org\/10.1038\/s41698-025-01229-5","journal-title":"npj Precis Onc"},{"key":"2347_CR302","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2183\/pjab.99.015","volume":"99","author":"A Ohtsu","year":"2023","unstructured":"Ohtsu A, Goto K, Yoshino T (2023) Improvement of patient care using cancer genomic profiling: SCRUM-\/CIRCULATE-Japan experience. Proc Japan Acad Ser B 99:241\u2013253. https:\/\/doi.org\/10.2183\/pjab.99.015","journal-title":"Proc Japan Acad Ser B"},{"key":"2347_CR303","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1093\/annonc\/mdx110","volume":"28","author":"A Aggarwal","year":"2017","unstructured":"Aggarwal A, Fojo T, Chamberlain C et al (2017) Do patient access schemes for high-cost cancer drugs deliver value to society?-lessons from the NHS Cancer Drugs Fund. Ann Oncol 28:1738\u20131750. https:\/\/doi.org\/10.1093\/annonc\/mdx110","journal-title":"Ann Oncol"},{"key":"2347_CR304","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/s41467-019-08718-9","volume":"10","author":"H Lu","year":"2019","unstructured":"Lu H, Arshad M, Thornton A et al (2019) A mathematical-descriptor of tumor-mesoscopic-structure from computed-tomography images annotates prognostic- and molecular-phenotypes of epithelial ovarian cancer. Nat Commun 10:764. https:\/\/doi.org\/10.1038\/s41467-019-08718-9","journal-title":"Nat Commun"},{"key":"2347_CR305","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2217\/fon.09.128","volume":"6","author":"S Singh","year":"2009","unstructured":"Singh S, Singh AP, Sharma B et al (2009) CXCL8 and its cognate receptors in melanoma progression and metastasis. Future Oncol 6:111\u2013116. https:\/\/doi.org\/10.2217\/fon.09.128","journal-title":"Future Oncol"},{"key":"2347_CR306","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.humimm.2014.04.018","volume":"75","author":"JM Weiss","year":"2014","unstructured":"Weiss JM, Alvord WG, Qui\u00f1ones OA et al (2014) CD40 expression in renal cell carcinoma is associated with tumor apoptosis, CD8() T cell frequency and patient survival. Hum Immunol 75:614\u2013620. https:\/\/doi.org\/10.1016\/j.humimm.2014.04.018","journal-title":"Hum Immunol"},{"key":"2347_CR307","doi-asserted-by":"publisher","first-page":"217821","DOI":"10.1016\/j.canlet.2025.217821","volume":"627","author":"S Sarvepalli","year":"2025","unstructured":"Sarvepalli S, Vadarevu S (2025) Role of artificial intelligence in cancer drug discovery and development. Cancer Lett 627:217821. https:\/\/doi.org\/10.1016\/j.canlet.2025.217821","journal-title":"Cancer Lett"},{"key":"2347_CR308","doi-asserted-by":"publisher","DOI":"10.1101\/2025.05.29.656813","author":"G Baltu\u0161yt\u0117","year":"2025","unstructured":"Baltu\u0161yt\u0117 G, Toleman I, Jones JO et al (2025) A network medicine framework for multi-modal data integration in therapeutic target discovery. bioRxiv - Bioinf. https:\/\/doi.org\/10.1101\/2025.05.29.656813","journal-title":"bioRxiv - Bioinf"}],"container-title":["Apoptosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-026-02347-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10495-026-02347-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-026-02347-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T12:58:46Z","timestamp":1779281926000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10495-026-02347-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":308,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2347"],"URL":"https:\/\/doi.org\/10.1007\/s10495-026-02347-6","relation":{},"ISSN":["1360-8185","1573-675X"],"issn-type":[{"value":"1360-8185","type":"print"},{"value":"1573-675X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"17 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"139"}}